

## **The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review**

**Authors:** Jessica Williams<sup>1</sup>, Sasha Barratte<sup>1</sup>, Tom Winfield<sup>1</sup>, Lauren Elston<sup>1</sup>, Katie McDermott<sup>1</sup>, David Jarrom<sup>1</sup>, Elise Hasler<sup>1</sup>, Caron Potter<sup>1</sup>, Ruth Lewis<sup>2</sup>, Alison Cooper<sup>2</sup>, Adrian Edwards<sup>2</sup>

1 Health Technology Wales, Wales, United Kingdom

2 Wales COVID-19 Evidence Centre, Wales, United Kingdom


### **Abstract:**

This is an update (literature search up to 15 March 2022) of a rapid review examining whether vaccination against SARS-CoV-2 (COVID-19) affects transmission of SARS-CoV-2.

Streamlined systematic methodologies were used to accelerate the review process.

The update identified 17 additional studies: 6 studies reported on transmission and 11 studies reported viral load. There was high heterogeneity across studies, which varied in design, participant characteristics and SARS-CoV-2 variants reported. Evidence from this update supports previous findings that that transmission of Omicron and Delta variants is lowest in booster-vaccinated people, followed by fully vaccinated people, with the highest rate of transmission in unvaccinated people. Additionally, some studies compared transmission between different variants or sub-variants; risk of transmission appears to be higher with Omicron than Delta, regardless of vaccination status.

**Funding statement:** Health Technology Wales was funded for this work by the Wales COVID-19 Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government.



## Wales COVID-19 Evidence Centre (WCEC) Rapid Review

### The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review

Update 02: Search to 15 March 2022

Report number – RR00054 (March 2022)

#### Rapid Review Details

**Review conducted by:** Health Technology Wales

**Review Team:** Jessica Williams, Sasha Barrate, Lauren Elston, Katie McDermott, Tom Winfield, David Jarrom, Elise Hasler, Carron Potter

**Review submitted to the WCEC:** March 2022

**Rapid Review report issued by the WCEC:** November 2022

**WCEC Team:**

Adrian Edwards, Alison Cooper, Ruth Lewis, Micaela Gal, Rebecca-Jane Law, Jane Greenwell and Ffion Coomber involved in drafting the Topline Summary, review and editing.

**This review should be cited as:**

RR00054. Wales COVID-19 Evidence Centre. A rapid review of the effect vaccination on Sars-CoV-2 (COVID-19) transmission. March 2022 update.

**Disclaimer:** The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest.

# The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review

Update 02: Search to 15 March 2022  
Report number – RR00054 (March 2022)

## FULL REPORT

### TOPLINE SUMMARY

#### What is a Rapid Review?

Our rapid reviews use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting rapid reviews, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1- 2 months, depending on the breadth and complexity of the research topic/ question(s), extent of the evidence base, and type of analysis required for synthesis.

This review is closely linked to a prior Rapid Review (RR) conducted by Wales COVID-19 Evidence Centre (WCEC) and published as: What is the risk of SARS-CoV-2 transmission in vaccinated populations? Report number – RR00012 (November 2021)

#### Background / Aim of Rapid Review

The COVID-19 vaccination programme has been successful in reducing the impact of severe COVID-19 disease on hospitalisation, morbidity and mortality. However, the effectiveness of COVID-19 vaccines against transmission is less clear, in particular for people with milder or asymptomatic infection, or in an era of new variants. We previously conducted a RR that aimed to examine evidence on the transmission risk of SARS-CoV-2 from vaccinated people to unvaccinated or vaccinated people (Report number – RR00012, November 2021). At the time of this previous review, the UK Health Security Agency (UKHSA) were setting up a living rapid review on the effect of COVID-19 vaccination on transmission of SARS-CoV-2. This Living RR was continued until January 2022 when the last update search was conducted (UKHSA, 2022). This RR represents an update (search up to 15 March 2022) of the last version of the UKHSA living RR, and addresses the following review questions:

- Does vaccination against COVID-19 affect transmission of SARS-CoV-2 to others, in the subgroup of people who contract COVID-19 post-vaccination?
- How does risk of onward transmission vary with vaccine type, completion of the vaccination course, duration after vaccination, at different baseline community transmission levels and SARS-CoV-2 variant in the vaccinated person?

#### Key Findings

##### *Extent of the evidence base*

The update identified 17 additional studies: 6 studies reported on transmission and 11 studies reported viral load. One additional ongoing RCT was also identified (estimated publication date December 2024.)

##### *Recency of the evidence base*

The update review included evidence published between 12 January 2022 (end date of last search) and 15 March 2022.

#### *Main findings*

- The main conclusions from the previous review were not changed from the inclusion of 17 additional studies in this update.
- Fully and booster-vaccinated cases (infected persons) transmit SARS-CoV-2 less than unvaccinated cases, particularly for pre-Delta and Wild-type variants. This difference diminishes with time since vaccine dose, particularly for the Delta and Omicron variants.
- Studies of viral load showed similar findings, with most pre-Delta studies showing fully vaccinated cases had larger Ct values or lower viral loads than unvaccinated cases, but most Delta and Omicron studies showed no clear difference in Ct values between fully vaccinated and unvaccinated cases.
- The risk of transmission of the Omicron variant was found to be higher compared with the Delta variant, regardless of vaccination status.
- There was insufficient evidence to examine whether transmission varies by vaccine type or at different baseline community transmission levels.

#### *Best quality evidence*

Two studies reporting on transmission were considered high quality (Andrejko et al. 2021, Lyngse et al. 2022a), and three studies of viral load were judged to be high quality (Lyngse et al. 2022a, Miguères et al. 2022, Qassim et al. 2022).

#### **Policy Implications**

- The findings indicate that transmission of Omicron and Delta variants is lowest in booster-vaccinated people, followed by fully vaccinated people, with the highest rate of transmission in unvaccinated people.
- Where studies have compared transmission between different variants or sub-variants, the risk of transmission appears to be higher with Omicron than Delta, regardless of vaccination status.
- Most studies were highly heterogeneous, so caution must be used when comparing results.
- Randomised controlled trials of vaccination assessing transmission to household members or other close contacts would help to understand the true vaccine effectiveness against transmission of SARS-CoV-2. However, these would need to account for the ongoing development of new variants, which may be challenging.

#### **Strength of Evidence**

The new evidence consists of observational studies that are mainly good to moderate quality. However, in almost all studies there is a high risk that factors other than vaccination may have affected the findings and biased the results in either direction. The studies also varied in design, participant characteristics and SARS-CoV-2 variants reported.

## Contents

<b>1. New evidence on transmission of SARS-CoV-2 after COVID-19 vaccination .....</b>	<b>6</b>
<b>2. New evidence on viral load in those who develop COVID-19 infection after being vaccinated.....</b>	<b>10</b>
<b>3. Inequalities.....</b>	<b>15</b>
<b>4. Limitations.....</b>	<b>15</b>
<b>5. Conclusion .....</b>	<b>16</b>
<b>6. Research needed.....</b>	<b>17</b>
<b>7. Acknowledgments .....</b>	<b>17</b>
<b>8. Summary Tables .....</b>	<b>17</b>
<b>9. References.....</b>	<b>50</b>
<b>10. Annex A: Methods.....</b>	<b>58</b>
<b>11. About the Wales COVID-19 Evidence Centre .....</b>	<b>64</b>

## 1. New evidence on transmission of SARS-CoV-2 after COVID-19 vaccination (Table 1)

In this update, there were 6 observational studies that directly assessed the effectiveness of vaccines in reducing the risk of transmission of SARS-CoV-2 from people who had COVID-19 (index cases) to household members or close contacts (secondary cases). Four of the studies were pre-prints: Allen et al. (2022a), Jalali et al. (2022), Lyngse et al. (2022a), Sriraman et al. (2022). The six studies were appraised using the Quality Criteria Checklist (QCC) tool. Two studies were assessed as high quality (Andrejko et al. 2021, Lyngse et al. 2022a), three were of medium quality (Allen et al. 2022a, Jalali et al. 2022, Sriraman et al. 2022) and one study was of low quality (Brandal et al. 2021). Five were cohort studies (Allen et al. 2022a, Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a, Sriraman et al. 2022) and one was a case-control study (Andrejko et al. 2021) One study provided data from the UK (Allen et al. 2022a), three from Europe (Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a), one from Asia (Sriraman et al. 2022) and one from USA (Andrejko et al. 2021). The dates of studies being conducted ranged between January 2020 and 23 January 2022.

Two studies focussed on the Omicron variant (Brandal et al. 2021, Lyngse et al. 2022a), one study looked at the Delta variant (Sriraman et al. 2022), two studies looked at both variants (Allen et al. 2022a, Jalali et al. 2022), and one study did not report the variant, but was likely it looked at Delta as the study dates went from February 2021 to November 2021 (Andrejko et al. 2021).

The studies included people who had received COVID-19 booster vaccinations (three doses), those who were fully vaccinated (two doses), those who were partially vaccinated (one dose), and those who were unvaccinated (no vaccine doses).

**Table 1** shows a summary of all transmission studies, including studies from both this update (with black text) and from the previous review (in grey text), and [Supplementary Table 1](#) shows full information for all transmission studies.

### 1.1 Evidence for the Omicron variant

#### 1.1.1 Transmission and vaccine effectiveness

There was one study from the previous review for transmission of Omicron variant SARS-CoV-2 (Lyngse et al. 2021). This study suggests that booster-vaccinated index cases transmit Omicron and Delta variant SARS-CoV-2 less than fully-vaccinated index cases, and that fully-vaccinated cases transmit less than unvaccinated index cases. There was little evidence that this was different for index cases with Omicron compared with Delta variant SARS-CoV-2. This study also suggested that there was little difference in Omicron variant SARS-CoV-2 transmission to fully vaccinated and unvaccinated household contacts, although there was less transmission to booster-vaccinated household contacts.

In addition to the study reported above, 3 studies included in this update (1 study just focused on Omicron and 2 studies looking at Omicron and Delta) looked at the difference in transmission of the Omicron variant from vaccinated and unvaccinated index cases. One

study included in this update looked at the effectiveness of vaccines in reducing Omicron SARS-CoV-2 transmission. These are described in more detail below.

### **Transmission**

Lyngse et al. (2022a) expanded on the study above by Lyngse et al. (2021) and assessed the transmission of two subvariants of Omicron (BA.1 and BA.2) to household members in 8,541 primary household cases in Denmark, from December 2021 to January 2022. The secondary attack rate (SAR) at seven days was estimated as 29% and 39% in households infected with Omicron BA.1 and BA.2, respectively. SAR was lowest in those index cases who were booster vaccinated compared to fully vaccinated and unvaccinated people. The study reported lower transmissibility in both BA.1 and BA.2 households when the index case was booster-vaccinated rather than fully vaccinated, with an odds ratio (OR) of 0.77 (95% confidence interval [CI]: 0.70 to 0.88) and 0.79 (95% CI: 0.64 to 0.98) for BA.1 and BA.2, respectively. There was no statistically significant difference in transmissibility in BA.1 households between unvaccinated and fully vaccinated index cases (OR: 0.93, 95% CI: 0.80 to 1.08). There was also no statistically significant difference in transmissibility between unvaccinated and fully vaccinated index cases in BA.2 households for unvaccinated index cases (OR: 1.21, 95% CI: 0.97 to 1.50) (Lyngse et al. 2022a).

Allen et al. (2022a) conducted a contact-tracing study of 51,281 SARS-CoV-2 positive people in England (13,680 with Omicron), between 5 and 11 December 2021, and found that SARs were consistently higher for Omicron than Delta for every stratum of vaccination dose for index cases or contacts.

For Delta cases, SARs were lowest among index cases who were booster-vaccinated in the household (6.2%, 95% CI: 5.3% to 7.1%) and non-household setting (3.1%, 95% CI: 2.1% to 4.2%), compared to unvaccinated people in the household setting (11.8%, 95% CI: 11.4% to 12.3%) and non-household setting (4.9%, 95% CI: 4.0% to 5.8%). The impact of index case vaccination on transmission rates for Omicron cases was considerably attenuated compared to Delta, with secondary transmission rates marginally lower for booster-vaccinated index Omicron cases (12.4%, 95% CI: 10.9% to 13.8%) compared to less than 3 doses (14.9%, 95% CI: 13.1% to 16.8%) or unvaccinated groups (15.8%, 95% CI: 14.7% to 17.0%) for all comparisons. In non-household settings, SAR was lower for Omicron cases in index cases who were vaccinated; the SAR was 8.8% (95% CI: 7.2% to 10.4%) for those who were unvaccinated, 7.5% (95% CI: 6.9% to 8.0%) for those who were fully vaccinated and 7.1% (95% CI: 5.7% to 8.4%) for those who were booster vaccinated (Allen et al. 2022a).

In addition, the proportion of index cases resulting in residential clustering was twice as high for Omicron (16.1%) compared to Delta (7.3%) (Allen et al. 2022a). The risk ratio of household clustering found that the overall risk ratio was 3.54 (95% CI: 3.29 to 3.81) for Omicron compared to Delta variants. Furthermore, for each of vaccination status there was an increased risk of household clustering for Omicron compared to Delta variants, most notably among index cases who were  $\geq 14$  days post their third vaccine dose, with a risk ratio of household clustering of 6.81 comparing Omicron and Delta variants (95% CI: 4.91 to 9.46) (Allen et al. 2022a).

Another contact-tracing study by Jalali et al. (2022), of 1,122 index cases and 2,169 household contacts in Norway, found an overall higher household ten-day SAR for the Omicron variant (51%, 95% CI: 48% to 54%) compared to the Delta variant (36%, 95% CI: 33% to 40%), with a relative risk of 1.41 (95% CI: 1.27 to 1.56). Index cases who were booster vaccinated were found to have a considerably higher risk (relative risk: 4.34; 95% CI: 1.52 to 25.16) of transmitting SARS-CoV-2 to their household contacts with Omicron compared to Delta. A similar trend was observed when the index case was unvaccinated or fully vaccinated, although the relative risks were lower (unvaccinated relative risk: 1.51, 95% CI: 1.30 to 1.77; fully vaccinated relative risk: 1.44, 95% CI: 1.24 to 1.70). There was not a significant increase in transmissibility in Omicron index cases who were partially vaccinated, compared to Delta (relative risk: 1.05, 95% CI: 0.76 to 1.52). Fully vaccinated index cases had a similar risk as unvaccinated index cases in Omicron transmission to their adult household members (relative risk: 1.04; 95% CI: 0.79 to 1.49). The same pattern was observed for the booster-vaccinated versus unvaccinated index cases (relative risk: 0.99; 95% CI: 0.68 to 1.49). In contrast, booster-vaccinated index cases with Delta had an 80% lower risk of transmission (0.18; 95% CI: 0.01 to 0.70) relative to unvaccinated index cases (Jalali et al. 2022).

### ***Vaccine effectiveness***

The effectiveness of vaccines in reducing infection for booster-vaccinated adult contacts was lower for Omicron (45%; 95% CI: 26% to 57%) compared to Delta (65%; 95% CI: 42% to 80%) but higher than for fully vaccinated adults (Jalali et al. 2022).

Brandal et al. (2021) conducted a cohort study of 110 people in Norway who attended a party, including someone who had recently travelled to South Africa and tested positive for Omicron (following a targeted exploration due to travel) in the days following the party. Most of the attendees (96%) were fully vaccinated with two vaccine doses (but no booster doses). The cohort was tested for Omicron in the 17 days following the party: 59% were confirmed cases and 14% were probable cases of Omicron. The total attack rate for the Omicron variant was 74% (Brandal et al. 2021). Although this study didn't compare vaccinated people with unvaccinated, or levels of vaccination, it was included as it provided transmission data for the Omicron variant in fully vaccinated people.

#### ***1.1.2 Summary of the evidence for Omicron transmission and vaccine effectiveness***

Evidence from the current review supports the findings of the study included in the previous review by Lyngse et al. (2021) that booster-vaccinated index cases transmit Omicron and Delta variant SARS-CoV-2 less than fully vaccinated index cases, who transmit less than unvaccinated index cases (Allen et al. 2022a, Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a). Furthermore, one of the studies included in this review found that the same is true for both subvariants of Omicron (BA.1 and BA.2) (Lyngse et al. 2022a).

The study by Lyngse et al. (2021) in the previous review and the studies identified in this review found evidence that the risk of transmission for index cases with Omicron was higher compared with Delta variant SARS-CoV-2, in those of all vaccination exposure statuses (Allen et al. 2022a, Jalali et al. 2022, Lyngse et al. 2021).



The evidence included in this review and the previous review also suggests that transmission was significantly less likely to contacts who had received booster vaccines compared to contacts who were fully vaccinated or partially vaccinated (Allen et al. 2022a, Lyngse et al. 2021).

## 1.2 Evidence for the Delta variant

There were 10 studies in the previous review (Allen et al. 2022b, Clifford et al. 2021, de Gier et al. 2021a, Eyre et al. 2022, Hsu et al. 2021, Kang et al. 2022, Lyngse et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021) which suggested fully vaccinated cases transmitted Delta variant SARS-CoV-2 less than unvaccinated cases. Two of these studies suggested that vaccine effectiveness against transmission of the Delta variant dropped substantially over time, though no studies in the update assessed this. Additionally, evidence from 9 studies in the previous review (Clifford et al. 2021, Eyre et al. 2022, Hsu et al. 2021, Lyngse et al. 2021, Lyngse et al. 2022b, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021, Yi et al. 2022) suggested that index cases typically transmitted SARS-CoV-2 to fully vaccinated contacts less than unvaccinated contacts.

Two studies included in this update looked at the difference in transmission of the Delta variant SARS-CoV-2 alone from vaccinated and unvaccinated index cases (Andrejko et al. 2021, Sriraman et al. 2022).

Andrejko et al. (2021) found that the odds of cases status were lower for both partially (OR: 0.30, 95% CI: 0.15 to 0.43) and fully vaccinated (OR: 0.25, 95% CI: 0.15 to 0.43) participants relative to unvaccinated participants. The study also reported that of the odds ratio of participants with case status was 3.02 (95% CI: 1.75 to 5.22) when high-risk exposures occurred with household members (versus other contacts), 2.10 (95% CI: 1.05 to 4.21) when exposures occurred indoors (versus outdoors), and 2.15 (95% CI: 1.27 to 3.67) when exposures lasted  $\geq 3$  hours (versus shorter durations) among unvaccinated and partially-vaccinated individuals; excess risk associated with such exposures was mitigated among fully-vaccinated individuals.

A prospective, observational study of 92 index cases in India (pre-print) by Sriraman et al. (2022) reported that the median household infection rate (HHR: defined as the number of confirmed positive members in the household at enrolment + number of new positive members at follow-up + number of new positive members at final telephone follow-up)/total number of individuals living in the same household) was significantly higher in people partially vaccinated with AstraZeneca (median HHR: 67%) and fully vaccinated with AstraZeneca (median HHR: 88%) compared to the unvaccinated (median HHR: 20%) (Sriraman et al. 2022).

### 1.2.1 Summary of the evidence for Delta transmission

Overall, evidence from 10 studies from the previous review (Allen et al. 2022b, Clifford et al. 2021, de Gier et al. 2021a, Eyre et al. 2022, Hsu et al. 2021, Kang et al. 2022, Lyngse et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021) and one of the studies in this review (Andrejko et al. 2021) suggested fully vaccinated cases transmitted Delta variant SARS-CoV-2 less than unvaccinated cases. However, the one new study identified in this review did not find a significant difference in the risk of transmission amongst vaccinated and unvaccinated people with the Delta variant (Sriraman et al. 2022).

Two studies from the previous review suggested that vaccine effectiveness against transmission of the Delta variant dropped substantially over time. Additionally, evidence from 9 studies from the previous review (Clifford et al. 2021, Eyre et al. 2022, Hsu et al. 2021, Lyngse et al. 2021, Lyngse et al. 2022b, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021, Yi et al. 2022) suggested that index cases typically transmitted SARS-CoV-2 to fully vaccinated contacts less than unvaccinated contacts.

### **1.3 Evidence for pre-Delta variants**

Evidence from 15 studies from the previous review (Allen et al. 2021, Braeye et al. 2021, de Gier et al. 2021b, Harris et al. 2021a, Harris et al. 2021b, Layan et al. 2022, Meyer et al. 2021, Prunas et al. 2022, Shah et al. 2021, Allen et al. 2022b, Bobdey et al. 2021, Clifford et al. 2021, Hsu et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021) suggested that fully vaccinated index cases transmitted pre-Delta variant and Wild-type SARS-CoV-2 to their contacts less than unvaccinated index cases, and this reduction was substantial (e.g. >50% reduction in transmission) in many studies. No new evidence was identified in this review.

## **2. New evidence on viral load in those who develop COVID-19 infection after being vaccinated (Table 2)**

In this update, we identified 11 additional observational studies that compared viral loads (predominantly using Ct values) between vaccinated and unvaccinated COVID-19 cases. Six were pre-prints (Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Lyngse et al. 2022a, Qassim et al. 2022, Sriraman et al. 2022). Of 11 studies, three studies were judged to be high quality (Lyngse et al. 2022a, Migueres et al. 2022, Qassim et al. 2022), six of medium quality (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Sriraman et al. 2022, Williams et al. 2021) and two were of low quality (Kissler et al. 2021, Barbosa et al. 2022). Of these, nine were cohort studies (Barbosa et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kissler et al. 2021, Lyngse et al. 2022a, Migueres et al. 2022, Qassim et al. 2022, Sriraman et al. 2022, Williams et al. 2021), and 2 were case-control studies (Accorsi et al. 2022, Kislaya et al. 2022a). One of the studies provided data from the UK (Williams et al. 2021), 4 from the USA (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kissler et al. 2021), 3 from Europe (Kislaya et al. 2022a, Lyngse et al. 2022a, Migueres et al. 2022), 2 from Asia (Qassim et al. 2022, Sriraman et al. 2022) and one from Brazil (Barbosa et al. 2022).

All studies were conducted between November 2020 and February 2022.

Three studies looked at the Omicron variant (Fall et al. 2022, Lyngse et al. 2022a, Qassim et al. 2022), three looked at both Omicron and Delta variants (Accorsi et al. 2022, Boucau et al. 2022, Kislaya et al. 2022a), one looked at the Delta variant (Sriraman et al. 2022), two looked at both Delta and Alpha variants (Kissler et al. 2021, Migueres et al. 2022), one looked at the Alpha variant (Williams et al. 2021), and one study included data without reporting the variant (Sriraman et al. 2022).

**Table 2** shows a summary of all viral load studies, including studies from both this update (with black text) and from the previous review (in grey text), and [Supplementary Table 2](#) shows full information for all viral load studies.

## 2.1 Evidence for the Omicron variant

Two studies included in the previous review compared the viral loads of Omicron and Delta variant cases (Puhach et al. 2022, Lyngse et al. 2021), though neither study reported the difference in Ct value between vaccinated and unvaccinated cases.

Six studies included in this update compared the viral load of Omicron in vaccinated and unvaccinated people (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Lyngse et al. 2022a, Qassim et al. 2022).

### 2.1.1 Viral load (Ct values)

A retrospective test-negative case-control analysis conducted in the USA measured median Ct values for three viral genes, stratified by variant and vaccination status, in 23,391 people with a positive SARS-CoV-2 test (Accorsi et al. 2022) . Median Ct values were significantly higher (q-value < 0.001), indicating lower viral load, in cases who were booster vaccinated versus those who were fully vaccinated, for both Omicron and Delta (Omicron N gene: 19.35 versus 18.52; Omicron ORF1ab gene: 19.25 versus 18.40; Delta N gene: 19.07 versus 17.52; Delta ORF1ab gene: 18.70 versus 17.28; Delta S gene: 23.62 versus 20.24). Among Omicron cases, median Ct values were slightly higher, indicating lower viral load, in samples from booster-vaccinated people versus unvaccinated people for the ORF1ab gene (19.25 versus 18.58) but not for the N gene (19.35 versus 18.71). Among Delta cases, median Ct values of the N, ORF1ab, and S genes were slightly higher (indicating lower viral load) in samples from people who were booster vaccinated versus unvaccinated (N gene: 19.07 versus 18.28; ORF1ab gene: 18.70 versus 17.84; S gene: 23.62 versus 19.58) (Accorsi et al. 2022).

A pre-print by Fall et al. (2022) reported no statistically significant difference when Ct values were compared between vaccinated and unvaccinated patients from: Omicron vaccinated groups ( n = 235), Omicron unvaccinated (n = 170), Delta vaccinated (n = 240), and Delta unvaccinated (n = 411) groups (Fall et al. 2022).

Kislaya et al. (2022a) conducted a case-case study in Portugal of 4,898 people aged 12 years and older with Omicron and 8,245 people aged 12 years and older with Delta variants. For patients aged 50 years and older, of which 18% were booster vaccinated, no statistically significant differences in mean Ct values by variant or vaccination status were observed. They did not find a significant mean difference in Ct values between these two variants for unvaccinated (-0.002, 95% CI: -0.6 to 0.6), partially vaccinated (-1.1, 95% CI: -2.6 to 0.36) or fully vaccinated people (-0.01, 95% CI: -0.2 to 0.2).

### ***Viral load (Ct values): Omicron subvariants***

A retrospective cohort study by Lyngse et al. (2022a) of 8,541 primary household cases in Denmark assessed the transmission of two subvariants of Omicron (BA.1 and BA.2) to

household members. The study reported that the distribution of sample Ct values for unvaccinated index cases was higher overall for BA.2 cases than for BA.1 cases. This was not the case for fully vaccinated and booster-vaccinated individuals, where the distribution appeared to be similar.

A similar cross-sectional study of 156,202 people in Qatar also investigated the effects of vaccination on the Ct values of Omicron subvariants BA.1 and BA.2 (Qassim et al. 2022). They found that compared to BA.1, BA.2 was associated with a lower Ct value (-3.53, 95% CI: -3.46 to -3.60). Ct values decreased with time since second and third vaccinations, following the established pattern of waning vaccine effectiveness. Ct values were highest for those who received their boosters in the month preceding the RT-qPCR test: 0.86 cycles (95% CI: 0.72 to 1.00) higher than for unvaccinated persons (Qassim et al. 2022).

### **2.1.2 Viral load (Ct values, time since vaccination)**

Considering time since completion of primary vaccination, Kislaya et al. (2022a) observed statistically significant differences between Delta and Omicron cases only for cases with less than 113 days since complete primary vaccination (mean difference: -0.70; 95% CI: -1.13 to -0.28), indicating slightly lower Ct (higher viral loads) in Omicron cases. There were no statistically significant differences between Delta and Omicron for cases more than 113 days since complete primary vaccination (Kislaya et al. 2022a).

In the pre-print mentioned above by Fall et al. (2022), when the Ct analysis was correlated to the days from the onset of symptoms for symptomatic patients, no significant differences were detected between Omicron and Delta, considering fully vaccinated, boosted, and unvaccinated cases separately. The authors concluded that there were no significant differences in viral RNA loads between Omicron and Delta infected individuals (Fall et al. 2022).

### **2.1.3 Viral load (time to viral clearance)**

A pre-print by Boucau et al. (2022) reported on how Omicron and Delta variants and vaccination status impact shedding of viable virus in an American longitudinal cohort study of 56 non-severely symptomatic patients with COVID-19. Viral load decay and time to negative PCR (time to PCR conversion) did not differ between participants infected with Omicron versus Delta (hazard ratio [HR]: 0.85, 95% CI: 0.44 to 1.61). Duration of shedding of viable virus, as measured by time to culture conversion, was also similar by variant (HR: 0.86, 95% CI: 0.47 to 1.58), with a median time to culture conversion of 6 days in both groups (IQR 4 to 8 days). In the overall cohort, there was no significant difference in time to PCR conversion ( $p = 0.08$ ) or culture conversion ( $p = 0.57$ ) by vaccination status.

### **2.1.4 Summary of the evidence for Omicron viral load**

Evidence from 2 studies in the previous review (Lyngse et al. 2021, Puhach et al. 2022) suggests there is little difference between the Ct values and genome copy numbers of Omicron and Delta variant SARS-CoV-2 cases, though infectious viral loads may be smaller in Omicron cases. This is supported by 3 studies in this current review (Fall et al. 2022, Kislaya et al. 2022a, Boucau et al. 2022). However, a large study found that median Ct values were significantly higher in cases with booster doses versus cases who were fully vaccinated, for both Omicron and Delta, and between individuals who were booster vaccinated and unvaccinated (Accorsi et al. 2022), and another study found slightly higher

viral loads in Omicron compared to Delta for those cases with less than 113 days since complete primary vaccination (Kislaya et al. 2022a).

Two studies in this review reported Ct values in the Omicron subtypes BA.1 and BA.2 (Lyngse et al. 2022a, Qassim et al. 2022). One study found that viral load was overall higher for BA.2 cases than for BA.1 cases in unvaccinated people, but this was not the case for fully vaccinated and booster-vaccinated individuals (Lyngse et al. 2022a). The other study also reported viral load as being higher for BA.2 cases and that Ct values were highest for those who received their boosters in the month preceding the PCR test compared to unvaccinated cases (Qassim et al. 2022).

## **2.2 Evidence for the Delta variant**

### **2.2.1 Viral load (Ct values)**

Evidence from 25 studies from the previous review (Acharya et al. 2021, Chia et al. 2021, Christensen et al. 2022, Elliott et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hirotsu et al. 2021, Hsu et al. 2021, Kale et al. 2021, Kang et al. 2022, Kerwin et al. 2021, Kislaya et al. 2022b, Levine-Tiefenbrun et al. 2021a, Levine-Tiefenbrun et al. 2022, Luo et al. 2021a, Lyngse et al. 2022b, Magalis et al. 2021, Pouwels et al. 2021, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021, Servellita et al. 2022, Siddle et al. 2022, Singanayagam et al. 2021, Yi et al. 2022) suggests mixed evidence for a difference in viral load between fully vaccinated and unvaccinated cases, with 17 studies suggesting no difference and 8 studies suggesting higher Ct values (lower viral load) in fully vaccinated cases.

A further three studies have been included in this update, which report on Ct levels in vaccinated and unvaccinated Delta cases (Barbosa et al. 2022, Miguères et al. 2022, Sriraman et al. 2022).

A study of 1,059 vaccinated healthcare workers in Brazil was published in a letter by Barbosa et al. (2022) and did not observe a significant difference in the viral load regardless of vaccine type or number of doses (Barbosa et al. 2022).

A prospective study in France by Miguères et al. (2022) reported that the nasopharyngeal viral loads of unvaccinated patients infected with the Delta variant were greater than in fully vaccinated patients (median 7.1 versus 6.64,  $p < 0.001$ ). The difference was similar for the Alpha variant but not significant (the authors suggest that this is due to the small sample size).

Another prospective study of 92 people with COVID-19 in India (pre-print) by (Sriraman et al. 2022) found no significant difference in the expelling pattern (high-risk emitters [people expelling >1000 viral copy numbers in 30 minutes], medium-risk emitters [A viral copy number of 100-999] and low-risk emitters [ $< 100$  copy numbers] of SARS-CoV-2) between partial, full and unvaccinated individuals, suggesting similar transmission risk. In addition, the viral load data showed that only patients in the partially and fully vaccinated AstraZeneca groups had a statistically significant reduction in viral load at follow-up (8 to 12 days after COVID-19 diagnosis), compared to other vaccines and unvaccinated cases.

Overall, evidence from 28 studies (25 studies from the previous review (Acharya et al. 2021, Chia et al. 2021, Christensen et al. 2022, Elliott et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hirotsu et al. 2021, Hsu et al. 2021, Kale et al. 2021, Kang et al. 2022, Kerwin et al. 2021, Kislaya et al. 2022b, Levine-Tiefenbrun et al. 2021a, Levine-Tiefenbrun et al. 2022, Luo et al. 2021a, Lyngse et al. 2022b, Magalis et al. 2021, Pouwels et al. 2021, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021, Servellita et al. 2022, Siddle et al. 2022, Singanayagam et al. 2021, Yi et al. 2022), and three studies from this update (Barbosa et al. 2022, Miguères et al. 2022, Sriraman et al. 2022), suggests mixed evidence for a difference in viral load between fully vaccinated and unvaccinated cases, with 17 studies suggesting no difference and 11 studies suggesting higher Ct values (lower viral load) in fully vaccinated cases.

### **2.2.2 Viral load (Ct values, time since vaccination)**

In the previous review, evidence from 2 studies (Levine-Tiefenbrun et al. 2021a), (Levine-Tiefenbrun et al. 2022) suggested that although Ct values are higher in fully and booster-vaccinated cases compared with unvaccinated cases (lower viral load) soon after vaccination, this difference drops quickly, with Ct values becoming similar between 61 and 120 days after vaccination.

### **2.2.3 Viral load (time to viral clearance)**

Evidence from 4 studies in the previous review (Hagan et al. 2021, Kang et al. 2022, Salvatore et al. 2021, Singanayagam et al. 2021) suggested that there was not a large or statistically significant difference in the time to viral clearance between fully vaccinated and unvaccinated cases.

Two studies investigating viral clearance were included in this update (Kissler et al. 2021, Sriraman et al. 2022).

SARS-CoV-2 viral dynamics were investigated in a prospective, longitudinal study, published in a letter by (Kissler et al. 2021), with 37 vaccinated and 136 unvaccinated people. Vaccinated individuals exhibited faster clearance compared to unvaccinated (mean: 5.5 days [95% CI: 4.6 to 6.5] versus 7.5 days [95% CI: 6.8 to 8.2]).

A prospective, observational study of 92 people with COVID-19 in India (pre-print) by Sriraman et al. (2022) found that among the vaccinated groups, the patients in the fully vaccinated Covaxin group (Bharat Biotech) had significantly higher mask positivity (proportion of patients expelling the virus) at 8 days (90%) compared to the partially and fully AstraZeneca vaccinated groups, suggesting that Covaxin patients may be clearing the virus slower than the AstraZeneca vaccinated groups and unvaccinated.

Overall, evidence from four studies in the previous review (Hagan et al. 2021, Kang et al. 2022, Salvatore et al. 2021, Singanayagam et al. 2021) did not suggest large or statistically significant differences in the time to viral clearance between fully vaccinated and unvaccinated cases. However, evidence from the 2 studies in this update suggest that vaccinated individuals exhibit faster viral clearance compared to unvaccinated (Kissler et al. 2021, Sriraman et al. 2022).

### **2.2.4 Infectious viral load (cytopathic effects)**

Evidence from 6 studies from the previous review (Hagan et al. 2021, Luo et al. 2021a, Peña-Hernández et al. 2022, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021), suggested there was little difference in cytopathic effects between fully vaccinated and unvaccinated cases. No new evidence was identified in this review for this outcome.

### **2.3 Evidence for pre-Delta variants**

From 27 studies from the previous review (Adamson et al. 2021, Abu-Raddad et al. 2022, Bailly et al. 2022, Blanquart et al. 2021, Boschi et al. 2021, Brunner-Ziegler et al. 2022, Costa et al. 2022, Emary et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hsu et al. 2021, Ioannou et al. 2021, Jacobson et al. 2022, Kislaya et al. 2022b, Kolobukhina et al. 2021, Lumley et al. 2021, Luo et al. 2021a, McEllistrem et al. 2021, Mostafa et al. 2021, Muhsen et al. 2021, Pajon et al. 2021, Pouwels et al. 2021, Regev-Yochay et al. 2021, Servellita et al. 2022, Smith et al. 2022, Tande et al. 2021, Thompson et al. 2021), there was evidence suggesting fully vaccinated cases had higher Ct values than unvaccinated cases (suggesting a lower viral load).

One study was identified in this update, which involved a retrospective analysis of test trending data of arrivals into the UK, and reported mean Ct values of positive cases from vaccinated (n = 274) and unvaccinated (n = 2,417) individuals as being 25.42 and 25.55, respectively, indicating no significant difference in the viral loads between these two groups (Williams et al. 2021).

## **3. Inequalities**

There was little evidence available to explore inequalities through variations across populations and subgroups, for example cultural variations or differences between ethnic, social, or vulnerable groups, either in the previous review or this update. As such, it was not possible to examine inequalities in this report.

## **4. Limitations**

The source of evidence in this review included peer-reviewed and pre-print articles. We did not conduct an extensive search of other sources (such as websites of public health organisations).

All studies were observational, comparing people who were vaccinated with those who were not. Therefore, there is a high risk in all studies that factors other than vaccination affected the results. This includes factors such as behaviour (including test seeking behaviour and behaviours likely to alter the risk of SARS-CoV-2 transmission), individual characteristics (such as age, sex, and deprivation), and COVID-19 characteristics (such as variant and symptom status). Partly due to this heterogeneity and partly due to a lack of evidence, we were unable to assess how the risk of onward transmission varied with different vaccine

types and baseline community transmission levels. Few studies (4 of 43 in the previous review, 5 of 17 in this update) were rated as high quality using the QCC tool, largely because few studies accounted for these risks well.

Most studies were heterogeneous, in terms of their location, prevalence of COVID-19 in the community, prevalence of past infections, dominant variant, background mitigations in place to limit transmission (including both local restrictions and personal protective measures), vaccination status of contacts, and availability of the vaccine to different groups, as well as the demographics of the index cases, household members and other close contacts. This makes direct comparison between studies and specific vaccines difficult. However, there were four studies offering medium to high quality evidence from the UK for the Delta variant (Allen et al. 2022a, Allen et al. 2022b, Eyre et al. 2022, Williams et al. 2021).

As with all reviews, the evidence identified may be subject to publication bias, whereby null or negative results are less likely to have been published by the authors. Ten of the 25 studies identified in this update were pre-prints and should be treated with caution as they have not been peer reviewed or subject to publishing standards and may be subject to change. This is in addition to 19 pre-prints or non-peer reviewed reports of the 43 studies identified in the previous review, although 2 of these have since been published (Gazit et al. 2021a, Luo et al. 2021b). In addition, our rapid review is limited by the fact that we are reviewing evidence from an emerging field that spans less than 1 year, and only 2 months for the currently dominant Omicron variant. Studies conducted in the COVID-19 context are conducted at pace with the aim to provide evidence in a timely manner, which sometimes impacts on the quality of the studies, both in term of design (especially limited statistical analyses) and reporting (insufficient detail). There is currently little evidence for the recently identified Omicron variant (Lyngse et al. 2021, Puhach et al. 2022).

## 5. Conclusion

The main conclusions from the previous review were not changed from the inclusion of 17 additional studies in this update.

There was evidence that fully and booster-vaccinated cases transmit SARS-CoV-2 less than unvaccinated cases, particularly for pre-Delta and Wild-type variants, and there was evidence suggesting that this difference is reduced with increasing time after the vaccine dose, particularly for the Delta and Omicron variants. The results from viral load studies are broadly supportive of these results, with most pre-Delta studies showing fully vaccinated cases have larger Ct values or lower viral loads than unvaccinated cases, and most Delta and Omicron studies showing no clear difference in Ct values between fully vaccinated and unvaccinated cases.

The transmission studies that reported Omicron data included in this update suggested that fully- and booster- vaccinated index cases can transmit both Omicron and Delta variant SARS-CoV-2 less than unvaccinated index cases, with the risk of transmission of Omicron being higher compared with the Delta variant SARS-CoV-2.



In almost all included studies (transmission and viral load) there is a high risk that factors other than vaccination may have affected the results, which may have biased the results in either direction. Most studies were also highly heterogeneous, so caution must be used when comparing results between different studies. Partly because of this heterogeneity, there was insufficient evidence to examine whether transmission varies by vaccine type or at different baseline community transmission levels.

## **6. Research needed**

Randomised controlled trials of vaccination assessing transmission to household members or other close contacts would help us to understand the true vaccine effectiveness against transmission of SARS-CoV-2, and from the previous review, we are aware of 2 ongoing RCTs, 1 in the US (NCT04811664, estimated publication date December 2021) and 1 in the UK (NCT04750356, estimated publication date December 2024), that could help estimate this. A cross-sectional school-based study to investigate SARS-CoV-2 transmission dynamics and the impact of different variants among confirmed cases and classmates is also ongoing (Bordas et al. 2022). These studies are described in [Supplementary Table 3](#). The results of these trials have not yet been published as of 25 May 2022.

## **7. Acknowledgments**

We would like to thank colleagues within the Public Health Advice, Guidance and Expertise function who either reviewed or input into aspects of the previous or this updated review, especially Helen McAuslane and Mario Aramouni. Also, thanks to Welsh Government and Public Health Wales stakeholders Simon Rolfe and Catherine Moore for their support of this work. We would also like to thank Sean Harrison and Rachel Clarke from the UK Health Security Agency (UKHSA), who had considerable contributions to the report.

## **Funding statement:**

Health Technology Wales was funded for this work by the Wales Covid-19 Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government.

## **8. Summary Tables**

**Table 1.** Summary of key findings from transmission studies

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
<b>Vaccination of <i>index</i><sup>4</sup>/<i>primary</i><sup>5</sup> cases on SARS-CoV-2 transmission to household contacts (effect estimates by index case vaccination status)</b>								
Allen (Allen et al. 2021)	UK, Mar-May 2021, Alpha	Household members, not stated	AstraZeneca or Pfizer	OR for transmission	Reference	0.94 (0.81 to 1.08)	0.76 (0.44 to 1.31)	
Allen / (Allen et al. 2022b)	UK, Mar-Jun 2021, Alpha (40%), Delta (43%)	Household members, not stated	Any	OR for transmission	Reference	0.94 (0.84 to 1.05)	0.73 (0.58 to 0.90)	
Bobdey (Bobdey et al. 2021)	India, Feb-Apr 2021, NR	Hospital dormitory residents, not stated	AstraZeneca	SAR	21.4%	4.3%		
Clifford (Clifford et al. 2021)	UK, Feb-Sept 2021, Alpha	Household members, 75% unvaccinated or partially vaccinated	AstraZeneca	RR reduction for transmission	Reference	-7% (-60% to 29%)	35% (-26% to 74%)	
			Pfizer		Reference	26% (-11% to 54%)	57% (5% to 85%)	
	AstraZeneca		Reference		14% (-11% to 52%)	42% (14% to 69%)		
	Pfizer		Reference		9% (-16% to 49%)	31% (-3% to 61%)		
			Any	SAR	31%	29%	11%	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
de Gier (de Gier et al. 2021b)	The Netherlands, Feb-May 2021, Alpha	Household contacts, 96% unvaccinated	AstraZeneca	RR reduction for transmission	Reference	21% (9% to 33%)	71% (63% to 77%)	
			Janssen		Reference	15% (4% to 26%)	58% (12% to 84%)	
			Moderna		Reference	-	77% (6% to 94%)	
			Pfizer		Reference	51% (8% to 74%)	88% (50% to 97%)	
					Reference	26% (12% to 37%)	70% (61% to 77%)	
de Gier (de Gier et al. 2021a)	The Netherlands, Aug-Sep 2021, Delta	Household contacts, 100% unvaccinated	Any	SAR	22%	17%	13%	
				RR reduction for transmission	Reference	46% (20% to 63%)	40% (20% to 54%)	
				SAR (≥60 days after 2 <sup>nd</sup> dose)	22%	-	15%	
				RR reduction for transmission (≥60 days after 2 <sup>nd</sup> dose)	Reference	-	55% (19% to 76%)	
		Household contacts, 0% unvaccinated		SAR	11%	6%	12%	
				RR reduction for transmission	Reference	38% (-2% to 62%)	63% (46% to 75%)	
				SAR (≥60 days after 2 <sup>nd</sup> dose)	11%	-	20%	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome		Effect estimate (95% CI)			
						Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
				RR reduction for transmission (≥60 days after 2 <sup>nd</sup> dose)		Reference	-	28% (-4% to 50%)	
Harris (Harris et al. 2021a, Harris et al. 2021b)	UK, Jan-Feb 2021, Alpha	Household members, 100% unvaccinated	AstraZeneca	SAR		10.1%	5.7%		
				OR for transmission		Reference	0.53 (0.43 to 0.63)		
			Pfizer	SAR		10.1%	6.2%		
				OR for transmission		Reference	0.51 (0.44 to 0.59)		
Jalali (Jalali et al. 2022)	Norway, 14 December 2020 to 23 January 2022, Omicron (> 90%)	Household members, 25% unvaccinated	mRNA vaccines or AstraZeneca	Omicron	SAR (95% CI)	0.57 (0.51 to 0.62)	0.42 (0.34 to 0.49)	0.51 (0.47 to 0.55)	0.46 (0.36 to 0.55)
					RR of transmission (95% CI)	Reference	1.01 (0.64 to 1.58)	1.04 (0.79 to 1.49)	0.99 (0.68 to 1.49)
				Delta	SAR (95% CI)	0.38 (0.33 - 0.42)	0.39 (0.29 to 0.51)	0.35 (0.31 to 0.40)	0.11 (0.02 to 0.29)
					RR of transmission (95% CI)	Reference	0.99 (0.51 to 1.64)	0.63 (0.46 to 0.89)	0.18 (0.01 to 0.70)
				RR of transmission with Omicron compared to Delta		1.51 (1.30 - 1.77)	1.05 (0.76 to 1.52)	1.44 (1.24 to 1.70)	4.34 (1.52 to 25.16)
Layan (Layan et al. 2022)	Israel, Dec 2020-Apr 2021, Alpha	Household members, 82% unvaccinated	Pfizer	SAR		40.7%	-	18.6%	
				RR reduction for transmission		Reference	-	78% (30% to 94%)	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)				
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated	
Lyngse (Lyngse et al. 2021)	Denmark, Dec 2021, Delta (81%), Omicron (19%)	Household members, not stated	AstraZeneca, Janssen, Moderna, Pfizer	OR for household transmission		1.41 (1.27 to 1.57)		Reference	0.72 (0.56 to 0.92)
Lyngse (Lyngse et al. 2022a)	Denmark, Dec 2021 to January 2022, Omicron (BA.2: 45%)	Household members, not stated  Study involved vaccination of index cases	AstraZeneca, Janssen, Moderna, Pfizer	OR for household transmission	BA.1	0.93 (0.80 to 1.08)		Reference	0.77 (0.70 to 0.88)
					BA.2	1.21 (0.97 to 1.50)		Reference	0.79 (0.64 to 0.98)
				SAR	BA.1	34%		31%	22%
					BA.2	43%		41%	34%
				OR for susceptibility	BA.1	1.23 (1.09 to 1.40)		Reference	0.65 (0.58 to 0.73)
					BA.2	1.10 (0.92 to 1.32)		Reference	0.80 (0.67 to 0.94)
Meyer (Meyer et al. 2021)	Germany, Jan-Mar 2021, Alpha	Household members, 67% unvaccinated	Pfizer	SAR		67%	22%		

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome		Effect estimate (95% CI)			
						Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Ng (Ng et al. 2021)	Singapore, Sep 2020-May 2021, Alpha	Household members, 70% unvaccinated	Moderna, Pfizer	SAR		12.9%	-	33.3%	
	25.8%					-	11.3%		
	Singapore, Sep 2020-May 2021, Delta			OR for household transmission	Reference	0.62 (0.22 to 1.69)	0.73 (0.38 to 1.40)		
Prunas (Prunas et al. 2022)	Israel, Jun 2020-Mar 2021, NR	Household members, NR	Pfizer	RR reduction for infectiousness		Reference	-	41% (10% to 73%)	
Salo* (Salo et al. 2021)	Finland, Dec 2020-Mar 2021, NR	Household members (spouses), 100% unvaccinated	Pfizer, Moderna	RR reduction for transmission weeks after first dose	2 weeks	Reference	9% (-29% to 35%)	-	
					10 weeks	Reference	43% (22% to 58%)	-	
Shah* (Shah et al. 2021)	UK, Dec 2020-Mar 2021, NR	Household members, 100% unvaccinated	AstraZeneca or Pfizer	SAR per 100 person years		9.40	5.93 <sup>1</sup>	2.98	
				HR for transmission		Reference	0.70 (0.63 to 0.78) <sup>1</sup>	0.46 (0.30 to 0.70)	
Sriraman (Sriraman et al. 2022)	India, July-Sept 2021, Delta (NR)	Household members, NR	Covaxin (Bharat Biotech), AstraZeneca	Median household infection risk by vaccine	AstraZeneca	20%	67%	88%	
					Covaxin		NR	50%	
<b>Vaccination of <i>index</i> cases on SARS-CoV-2 transmission to close contacts (effect estimates by index case vaccination status)</b>									

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Brandal (Brandal et al. 2021)	Norway, November and December 2021, <b>Omicron</b>	Close contacts in a party	BioNTech/Pfizer, Moderna	Total attack rate	NR	NR	74%	
Braeye (Braeye et al. 2021)	Belgium, Jan-Jun 2021, <b>Alpha</b>	High risk contacts, 93% unvaccinated	AstraZeneca	RR reduction for transmission	Reference	-3% (-10% to 2%)	8% (-79% to 63%)	
			Janssen		Reference	NA	27% (-23% to 62%)	
			Moderna		Reference	41% (23% to 57%)	52% (22% to 69%)	
			Pfizer		Reference	8% (-79% to 63%)	16% (8% to 22%)	
De Gier (de Gier et al. 2021b)	The Netherlands, Feb-May 2021, <b>Alpha</b>	Other close contacts, 96% unvaccinated	Any	SAR	11%	10%	9%	
				RR reduction for transmission	Reference	22% (9% to 33%)	22% (5% to 43%)	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Alpha (57%), Delta (40%)	Close contacts, not stated	AstraZeneca, Janssen, Moderna, Pfizer, Sinopharm, Sputnik	SAR	37.8%	-	10.1%	
				OR for transmission	Reference	-	0.21 (0.16 to 0.27)	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)						
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated			
Kang (Kang et al. 2022)	China, May-Jun 2021, <b>Delta</b>	Close contacts, 55% unvaccinated	NR	SAR	1.3%	2.5%	0.4%				
				OR for transmission	Reference	-	0.35 (0.12 to 0.84)				
Martinez-Baz (Martinez-Baz et al. 2021)	Spain, Apr-Aug 2021, Alpha (52%), Delta (40%)	Close contacts, 47% unvaccinated	AstraZeneca, Moderna, Pfizer, Janssen	SAR	25%	19%	18%				
<b>Vaccination of <i>index</i> cases on SARS-CoV-2 transmission to household and other contacts (effect estimates by index case vaccination status)</b>											
Allen (Allen et al. 2022a)	England, 5-11 December 2021. <b>Delta</b> . <b>Omicron</b> accounted for 26.6% cases in England during study period	Close contacts, 33.9% of Delta contacts and 22.9% of Omicron contacts were unvaccinated	NR	SAR	Delta	household	11.8% (11.4% to 12.3%)	9.6% (8.8% to 10.4%)	10.0% (9.6% to 10.3%)	6.2% (5.3% to 7.1%)	
						Non-household	4.9% (4.0% to 5.8%)	4.7% (3.2% to 6.3%)	3.7% (3.4% to 4.1%)	3.1% (2.1% to 4.2%)	
						Omicron	Household	15.8% (14.7% to 17.0%)	14.9% (13.1% to 16.8%)	15.8% (15.1% to 16.5%)	12.4% (10.9% to 13.8%)
							Non-household	8.8% (7.2% to 10.4%)	6.7% (4.6% to 8.9%)	7.5% (6.9% to 8.0%)	7.1% (5.7% to 8.4%)



Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome		Effect estimate (95% CI)			
						Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
				RR Omicron vs Delta	Household	1.33 (1.23 to 1.44)	1.55 (1.34 to 1.81)	1.58 (1.50 to 1.67)	1.99 (1.66 to 2.39)
					Non-household	1.33 (1.23 to 1.44)	1.55 (1.34 to 1.81)	1.58 (1.50 to 1.67)	1.99 (1.66 to 2.39)
Eyre (Eyre et al. 2022)	England, Jan-Jul 2021, Alpha or Delta	All contacts, 45% unvaccinated	AstraZeneca	SAR		46%	35%	28%	
			Pfizer			46%	26%	21%	
	AstraZeneca		Rate ratio for transmission	Reference	0.90 (0.86 to 0.94)	0.48 (0.30 to 0.78)			
	Pfizer			Reference	0.88 (0.85 to 0.91)	0.32 (0.21 to 0.48)			
	AstraZeneca		Reduction in transmission, weeks after second dose	2 weeks	-	-	52% (22% to 70%)		
	AstraZeneca			12 weeks	-	-	38% (-1% to 62%)		
	Pfizer			2 weeks	-	-	68% (52% to 79%)		
	Pfizer			12 weeks	-	-	52% (29% to 67%)		
				AstraZeneca	Rate ratio for transmission	Reference	0.95 (0.91 to 0.99)	0.76 (0.70 to 0.82)	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome		Effect estimate (95% CI)			
						Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
England, Jan-Jul 2021, Delta			Pfizer			Reference	0.83 (0.81 to 0.86)	0.50 (0.39 to 0.65)	
			AstraZeneca	Reduction in transmission, weeks after second dose	2 weeks	-	-	24% (18% to 30%)	
					12 weeks	-	-	2% (-2% to 6%)	
			Pfizer	Reduction in transmission, weeks after second dose	2 weeks	-	-	50% (35% to 61%)	
					12 weeks	-	-	24% (20% to 28%)	
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	All contacts, not stated	AstraZeneca, Pfizer	SAR		23%	37%	25%	
<b>Vaccination of contacts on SARS-CoV-2 transmission to household contacts (effect estimates by contact vaccination status)</b>									
Clifford (Clifford et al. 2021)	UK, Feb-Sept 2021, Alpha	Household members, 23% unvaccinated	AstraZeneca	RR reduction for transmission		Reference	3% (-38% to 39%)	26% (-39% to 73%)	
			Pfizer			Reference	53% (7% to 83%)	71% (12% to 95%)	
	AstraZeneca		Reference			2% (-19% to 31%)	14% (-5% to 46%)		
	Pfizer		Reference			4% (-21% to 44%)	24% (-2% to 64%)		

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
De Gier (de Gier et al. 2021b)	The Netherlands, Feb-May 2021, Alpha	Household contacts, 98% unvaccinated index cases	Any	RR reduction for transmission	Reference	23% (14% to 50%)	75% (72% to 78%)	
			AstraZeneca		Reference	2% (-11% to 14%)	87% (77% to 93%)	
			Janssen		Reference	NA	12% (-71% to 54%)	
			Moderna		Reference	33% (-27% to 64%)	91% (79% to 97%)	
			Pfizer		Reference	-18% (-43% to 2%)	65% (60% to 70%)	
Gazit (Gazit et al. 2021b, Gazit et al. 2021a) <sup>3</sup>	Israel, Dec-Mar 2021, NR	Household members, 8% unvaccinated index cases	Pfizer	SAR	37.5%	41.7%	7.5%	
				RR reduction for transmission	Reference	-	80% (74% to 85%)	
Jalali (Jalali et al. 2022)	Norway, 14 December 2021 to 23 January 2022, <b>Omicron (&gt; 90%)</b>	Household members, 25% unvaccinated	mRNA vaccines or AstraZeneca	Omicron SAR	0.59 (0.53 to 0.64)	0.57 (0.48 to 0.66)	0.50 (0.46 to 0.54)	0.38 (0.31 to 0.44)
				Delta SAR	0.47 (0.41 to 0.52)	0.34 (0.23 to 0.46)	0.32 (0.28 to 0.37)	0.20 (0.11 to 0.30)
Layan (Layan et al. 2022)	Israel, Dec 2020-Apr 2021, <b>Alpha</b>	Household members, 92% unvaccinated	Pfizer	SAR <sup>2</sup>	75.0%	-	10.8%	
				RR reduction for transmission <sup>2</sup>	Reference	-	93% (83% to 97%)	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Lyngse (Lyngse et al. 2022b)	Denmark, Jun-Nov 2021, Delta	Household members, 52% unvaccinated	AstraZeneca, Janssen, Moderna, Pfizer	SAR	28%	-	15%	
Lyngse (Lyngse et al. 2021)	Denmark, Dec 2021, Omicron	Household members, not stated	AstraZeneca, Janssen, Moderna, Pfizer	SAR	29%		32%	25%
				OR for transmission	1.04 (0.87 to 1.24)		Reference	0.54 (0.40 to 0.71)
	SAR			28%		19%	11%	
	OR for transmission			2.31 (2.09 to 2.55)		Reference	0.38 (0.32 to 0.46)	
Ng (Ng et al. 2021)	Singapore, Sep 2020-May 2021, Delta	Household members, 70% unvaccinated	Moderna, Pfizer	SAR	25.8%	-	11.3%	
				OR for transmission	Reference	0.61 (0.33 to 1.12)	0.33 (0.17 to 0.63)	
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	Household members, not stated	AstraZeneca, Pfizer	SAR	38%	18%	25%	
Yi (Yi et al. 2022)	South Korea, Aug 2021, Delta	Household members, 39% unvaccinated	Pfizer	SAR	27.8%	25%	12.5%	
<b>Vaccination of contacts on SARS-CoV-2 transmission to other contacts (effect estimates by contact vaccination status)</b>								

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Braeye (Braeye et al. 2021)	Belgium, Jan-Jun 2021, Alpha	High risk contacts, 100% unvaccinated index cases	AstraZeneca	RR reduction for transmission	Reference	31% (27% to 35%)	55% (11% to 82%)	
			Janssen		Reference	NA	57% (21% to 81%)	
			Moderna		Reference	65% (57% to 81%)	85% (79% to 90%)	
			Pfizer		Reference	41% (37% to 45%)	74% (72% to 76%)	
De Gier (de Gier et al. 2021b)	The Netherlands, Feb-May 2021, Alpha	Other close contacts, 98% unvaccinated index cases	Any	RR reduction for transmission	Reference	28% (17% to 38%)	79% (74% to 84%)	
Martinez-Baz (Martinez-Baz et al. 2021)	Spain, Apr-Aug 2021, Alpha (52%), Delta (40%)	Close contacts, 47% unvaccinated	All	SAR	34%	18%	14%	
			AstraZeneca			19%	18%	
			Janssen			-	21%	
			Moderna			14%	8%	
			Pfizer			17%	13%	
			AstraZeneca	RR reduction for transmission	Reference	41% (34% to 48%)	54% (48% to 60%)	
			Janssen			-	50% (42% to 57%)	

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)					
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
			Moderna			66% (56% to 73%)	82% (78% to 86%)			
			Pfizer			57% (52% to 61%)	69% (66% to 72%)			
<b>Vaccination of contacts on SARS-CoV-2 transmission to household and other contacts (effect estimates by contact vaccination status)</b>										
Allen (Allen et al. 2022a)	England, 5-11 December 2021. <b>Delta</b> . <b>Omicron</b> accounted for 26.6% cases in England during study period	Close contacts, 47.8% of unvaccinated had Delta and 20.8% had Omicron	NR	Risk of household clustering aRR for Omicron vs Delta		3.19 (2.79 to 3.64)	4.09 (3.19 to 5.23)	3.56 (3.25 to 3.90)	6.81 (4.91 to 9.46)	
				SAR	Delta	Household	12.9% (12.4% - 13.5%)	10.6% (9.7% to 11.5%)	11.2% (10.8% to 11.6%)	7.6% (6.9% to 8.3%)
						Non-household	5.1% (3.4% - 6.8%)	6.0% (3.2% to 8.9%)	5.9% (5.1% to 6.7%)	3.0% (2.2% to 3.8%)
				SAR	Omicron	Household	15.9% (14.8% - 17.0%)	14.8% (12.8% to 16.8%)	18.3% (17.4% to 19.3%)	16.1% (14.5% to 17.7%)
						Non-household	10.1% (7.4% to 12.8%)	7.4% (3.8% to 11.0%)	9.6% (8.4% to 10.9%)	7.3% (5.7% to 9.0%)

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome		Effect estimate (95% CI)				
						Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated	
				RR Omicron vs Delta		Household	1.23 (1.14 to 1.32)	1.40 (1.19 to 1.63)	1.64 (1.55 to 1.75)	2.13 (1.87 to 2.43)
						Non-household	1.99 (1.32 to 2.99)	1.22 (0.62 to 2.39)	1.64 (1.43 to 1.87)	2.43 (1.80 to 3.29)
Andrejko (Andrejko et al. 2021)	USA (California) February-November 2021, NR	High-risk exposures with household contacts and non-household contacts (75.3% unvaccinated)	Pfizer/BioNTech, Moderna, Janssen	OR		Reference	0.30 (0.15 to 0.43)	0.25 (0.15 to 0.43)		
Eyre (Eyre et al. 2022)	England, Jan-Jul 2021, Alpha or Delta	All contacts, 55% unvaccinated index cases	AstraZeneca	SAR	52%	32%	22%			
			Pfizer		52%	32%	17%			
	AstraZeneca		Rate ratio for transmission	Reference	0.94 (0.91 to 0.98)	0.40 (0.27 to 0.59)				
	Pfizer			Reference	0.85 (0.82 to 0.88)	0.15 (0.11 to 0.21)				
AstraZeneca	Reference	0.69 (0.66 to 0.72)		0.42 (0.38 to 0.45)						

Study	Country, time, dominant variant	Contact type, vaccination status	Vaccine	Outcome	Effect estimate (95% CI)			
					Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
	England, Jan-Jul 2021, Delta		Pfizer		Reference	0.67 (0.65 to 0.69)	0.19 (0.16 to 0.23)	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Alpha (57%), Delta (40%)	Close contacts, 50% unvaccinated	AstraZeneca, Janssen, Moderna, Pfizer, Sinopharm, Sputnik	OR for transmission	Reference	-	1.26 (0.90 to 1.77)	
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	All contacts, not stated	AstraZeneca, Pfizer	SAR	34%	15%	22%	

CI = confidence interval or credible interval, HR = hazard ratio, NR = not reported, OR = odds ratio, RR = relative risk, SAR = secondary attack rate

\*These studies looked at all healthcare workers, not just those with a confirmed SARS-CoV-2 infection, so these results include the effect of vaccines on preventing COVID-19 as well as on reducing transmission from index cases with COVID-19

<sup>1</sup>These results are for both partially and fully vaccinated participants

<sup>2</sup>These effect estimates are for contacts who were fully vaccinated and isolated compared with contacts who were unvaccinated and did not isolate

<sup>3</sup>Updated from previous report (pre-print was published or updated)

<sup>4</sup> Index case: first person noticed by authorities that makes them aware of an outbreak (patient 0)

Studies with black text are from this updated search; studies with grey text are from a previous search



**Table 2.** Summary of key findings from studies reporting viral load

Study	Country, time, dominant variant	Vaccine	Outcome		Effect estimate			
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
<b>Booster vaccinated, Omicron variant</b>								
Accorsi (Accorsi et al. 2022)	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%	Pfizer and Moderna	Difference in median Ct values	ORF1ab gene	3 doses vs 2	-	3 doses: 19.25 (NR) 2 doses: 18.40 (NR)	0.85 (0.45 to 1.26)
					3 doses vs unvaccinated	18.58 (NR)	19.25 (NR)	0.67 (0.23 to 1.12)
				N gene	3 doses vs 2	-	3 doses: 19.35 (NR) 2 doses: 18.52 (NR)	0.83 (0.51 to 1.20)
					3 doses vs unvaccinated	18.71 (NR)	19.35 (NR)	0.65 (0.28 to 1.03)
Boucau (Boucau et al. 2022)	USA, July 2021 to January 2022. In the study, 66% had Delta and 34% had Omicron	Johnson & Johnson/Janssen only one named but others also used	Viral load decay and time to negative PCR (time to PCR conversion)		Reference	1.16 (95% CI: 0.39, 3.45)	p = 0.80	
			Duration of shedding of viable virus (time to culture conversion)		Reference	1.36 (95% CI: 0.46, 4.03)	p = 0.57	
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values of samples collected ≤ 5 days from onset of symptoms		11 to 33 <sup>5</sup>	11 to 34 <sup>5</sup>	NR	
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AstraZeneca Johnson & Johnson/Janssen	Range of Ct values in people aged 50 years or more		11 to 29 <sup>5</sup>	10 to 29.5 <sup>5</sup>	NR	
Lyngse (Lyngse et al. 2022a)	Denmark, Dec 2021 to January 2022, Omicron (BA.2: 45%)	Pfizer/BioNTech, Moderna, AstraZeneca Johnson & Johnson/Janssen	BA.1	Median Ct value	27.02	27.65	NR	
				Mean Ct value	27.20	27.72	NR	
			BA.2	Median Ct value	25.42	27.09	NR	
				Mean Ct value	26.07	27.72	NR	
Qassim (Qassim et al. 2022)	Quatar, Dec 2021 – Feb 2022, BA.2 (NR)	Pfizer, Moderna	Ct value	≤1 month before the RT-qPCR test	Reference	0.86 (0.72, 1.00)	p <0.001	
				> 1 month before the RT-qPCR test	Reference	0.28 (0.14, 0.42)	p <0.001	

Study	Country, time, dominant variant	Vaccine	Outcomes			Effect estimate		
						Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
<b>Fully vaccinated, Omicron variant</b>								
Accorsi (Accorsi et al. 2022)	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%	Pfizer and Moderna	Difference in median Ct values	ORF1ab gene	3 doses vs 2	-	3 doses: 19.25 (NR) 2 doses: 18.40 (NR)	0.85 (0.45 to 1.26)
				N gene	2 doses vs unvaccinated	18.58 (NR)	18.40 (NR)	-0.18 (-0.49 to 0.13)
					3 doses vs 2	-	3 doses: 19.35 (NR) 2 doses: 18.52 (NR)	0.83 (0.51 to 1.20)
					2 doses vs unvaccinated	18.71 (NR)	18.52 (NR)	-0.19 (-0.49 to 0.09)
Boucau (Boucau et al. 2022)	USA, July 2021 to January 2022. In the study, 66% had Delta and 34% had Omicron	Johnson & Johnson/Janssen only one named but others also used	Viral load decay and days to negative PCR (tdays to PCR conversion)		Reference	-	0.51 (95% CI: 0.23, 1.09)	
			Duration of shedding of viable virus (days to culture conversion)		Reference	0.82 (95% CI: 0.39, 1.71)	p = 0.60	
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values from all available Ct samples			11 to 33 <sup>5</sup>	11 to 34 <sup>5</sup>	NR
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values			18.6 (4.8)	18.4 (4.5)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: -0.002(-0.6 to 0.6)

Study	Country, time, dominant variant	Vaccine	Outcomes		Effect estimate		
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
			Mean (standard deviation) Ct values for time since fully vaccinated	Completion < 113 days	-	18.5 (4.5)	Confounder-adjusted mean difference between Omicron and Delta: -0.7(-1.13 to -0.28)
				Completion 113-168 days	-	18.4 (4.5)	Confounder-adjusted mean difference between Omicron and Delta: 0.13(-0.14 to 0.39)
				Completion 169+ days	-	18.3 (4.6)	Confounder-adjusted mean difference between Omicron and Delta: 0.32(-0.08 to 0.73)
Lyngse (Lyngse et al. 2022a)	Denmark, Dec 2021 to January 2022, Omicron (BA.2: 45%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	BA.1	Median Ct value	27.02	27.33	NR
				Mean Ct value	27.20	27.50	NR
			BA.2	Median Ct value	25.42	26.97	NR
				Mean Ct value	26.07	26.88	NR
Qassim (Qassim et al. 2022)	Quatar, Dec 2021 – Feb 2022, BA.2 (NR)	Pfizer, Moderna	Ct value	2 doses < 3 months before PCR test	Reference	0.23 (0.00, 0.46)	p = 0.048
				2 doses 3 to < 6 months before PCR test	Reference	-0.05 (-0.15, 0.06)	p = 0.389
				2 doses 6 to < 9 months before PCR test	Reference	-0.48 (-0.56, -0.40)	p < .001
				2 doses ≥ 9 months before PCR test	Reference	-0.43 (-0.53, -0.33)	p < .001
<b>Partially vaccinated, Omicron variant</b>							
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values		18.6 (4.8)	18.5 (4.6)	Confounder-adjusted mean difference between Omicron

Study	Country, time, dominant variant	Vaccine	Outcomes			Effect estimate		
						Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
								and Delta for unvaccinated: -0.002 (-0.6 to 0.6)
Qassim (Qassim et al. 2022)	Qatar, Dec 2021 – Feb 2022, BA.2 (NR)	Pfizer, Moderna	Ct value (one vaccine dose)			Reference	-0.34 [-0.67, -0.00]	p =0.050
<b>Booster vaccinated, Delta variant</b>								
Accorsi (Accorsi et al. 2022)	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%	Pfizer and Moderna	Difference in median Ct values	ORF1ab gene	3 doses vs 2	-	3 doses: 18.70 (NR) 2 doses: 17.28 (NR)	1.43 (0.92 to 2.07)
					3 doses vs unvaccinated	17.84 (NR)	18.70 (NR)	0.87 (0.28 to 1.51)
				N gene	3 doses vs 2	-	3 doses: 19.07 (NR) 2 doses: 17.52 (NR)	1.56 (0.95 to 2.07)
					3 doses vs unvaccinated	18.28 (NR)	19.07 (NR)	0.80 (0.19 to 1.33)
				S gene	3 doses vs 2	-	3 doses: 23.62 (NR) 2 doses: 20.24 (NR)	3.38 (2.74 to 3.98)
					3 doses vs unvaccinated	19.58 (NR)	23.62 (NR)	4.05 (3.46 to 4.61)
Levine-Tiefenbrun (Levine-Tiefenbrun et al. 2021a)	Israel, Jun-Sep 2021, Delta (93%)	Pfizer	Mean Ct value			27.7 (5.0)	29.1 (4.7)	2.43 (1.97 to 2.89)
Levine-Tiefenbrun (Levine-Tiefenbrun et al. 2022)	Israel, Jun-Nov 2021, Delta (>93%)	Pfizer	Mean Ct values	7-30 days after booster dose	26.8 (5.0)	29.4 (4.7)	2.7 (2.3 to 3.0)	
				31-60 days after booster dose		28.5 (4.4)	1.3 (0.7 to 1.9)	
				61-120 days after booster dose		28.9 (4.5)	0.8 (-0.1 to 1.8)	

Study	Country, time, dominant variant	Vaccine	Outcomes	Effect estimate				
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value		
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values of samples collected ≤ 5 days from onset of symptoms	Range: 8 to 34 <sup>5</sup>	Range: 8 to 33 <sup>5</sup>	NR		
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Range of Ct values in people aged 50 years or more	9 to 28 <sup>5</sup>	9 to 30 <sup>5</sup>	NR		
<b>Fully vaccinated, Delta variant</b>								
Acharya (Acharya et al. 2021)	US, Jun-Aug 2021, Delta (>95%)	NR	Median Ct value (UeS)	22.7 (19.1 to 27.3)	22.2 (18.9 to 26.9)	p=0.54		
			Median Ct (UeS, symptomatic)	21.9 (18.9 to 26.1)	21.2 (18.9 to 25.8)	p=0.62		
			Median Ct (UeS, asymptomatic)	23.6 (19.8 to 28.7)	24.0 (20.3 to 29.1)	p=0.89		
			Median Ct (HYT, asymptomatic)	25.7 (22.9 to 28.2)	26.1 (22.7 to 28.8)	p=0.80		
Accorsi (Accorsi et al. 2022)	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%	Pfizer and Moderna	Difference in median Ct values	ORF1ab gene	3 doses vs 2	-	3 doses: 18.70 (NR) 2 doses: 17.28 (NR)	1.43 (0.92 to 2.07)
					2 doses vs unvaccinated	17.84 (NR)	17.28 (NR)	-0.56 (-0.95 to -0.30)
				N gene	3 doses vs 2	-	3 doses: 19.07 (NR) 2 doses: 17.52 (NR)	1.56 (0.95 to 2.07)
					2 doses vs unvaccinated	18.28 (NR)	17.52 (NR)	-0.76 (-1.08 to -0.42)
				S gene	3 doses vs 2	-	3 doses: 23.62 (NR) 2 doses: 20.24 (NR)	3.38 (2.74 to 3.98)
					2 doses vs unvaccinated	19.58 (NR)	20.24 (NR)	0.67 (0.29 to 1.04)

Study	Country, time, dominant variant	Vaccine	Outcomes	Effect estimate			
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Barbosa (Barbosa et al. 2022)	Brazil, Jan-Oct 2021, NR	Sinovac	Median Ct (symptomatic)	1 dose	NR	22.5 (21 to 28)	p = 0.44
				2 doses		19 (17 to 24)	p > 0.99
		AstraZeneca		1 dose		23 (18 to 26)	p > 0.99
				2 doses		22 (16 to 30)	p = 0.66
Blanquart (Blanquart et al. 2021)	France, Jun-Jul 2021, Delta (91%)	NR	Difference in Ct value (symptomatic)	-	-	-0.25 (-0.96 to 0.46)	
	France, Jun-Jul 2021, Delta (100%)		Difference in Ct value (asymptomatic)	-	-	1.68 (1.03 to 2.33)	
			Difference in Ct values (symptomatic)	-	-	-0.14 (-0.99 to 0.72)	
			Difference in Ct values (asymptomatic)	-	-	1.42 (0.61 to 2.24)	
Chia (Chia et al. 2021)	Singapore, Apr-Jun 2021, Delta (100%)	Pfizer & Moderna	Median Ct value (first positive test)	18.8 (14.9 to 22.7)	19.2 (15.2 to 22.2)	p=0.929	
			Median Ct value (symptom onset)	21.9 (18.8 to 31.2)	19.2 (16.6 to 21.5)	p=0.279	
Christensen (Christensen et al. 2022)	US, Mar-Aug 2021, Delta (77%)	Pfizer, Moderna, Janssen	Median Ct value (Abbott assay)	22.1	20.5	p=0.0018	
			Median Ct value (Hologic Panther assay)	23.5	22.2	p=0.0348	
Elliott (Elliott et al. 2021)	UK, Jun-Jul 2021, Delta (100%)	NR	Median Ct value	23.1 (20.3 to 25.8)	27.6 (25.5 to 29.7)	p=0.01	
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, Delta (100%)	AstraZeneca	Median Ct value (symptomatic)	17.1	17.3	NR	
		Pfizer		17.1	18.2	NR	
		AstraZeneca	Proportion of reduction in transmission mediated via index case Ct values at diagnosis	-	-	23% (17% to 33%)	
		Pfizer		-	-	7% (5% to 10%)	
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values from all available Ct samples	8 to 34 <sup>5</sup>	8 to 33 <sup>5</sup>	NR	
Griffin (Griffin et al. 2021)	US, May-Jul 2021, Delta (>90%)	Janssen, Moderna, Pfizer	Median Ct value ( <i>ORF1ab</i> gene)	18.8	19.0	p>0.05	
			Median Ct value ( <i>N</i> gene)	19.3	19.5		
			Median Ct value ( <i>SC2N</i> gene)	19.3	19.4		
Hagan (Hagan et al. 2021)	US, Jul-Aug 2021, Delta (100%)	Janssen, Moderna, Pfizer	Median time between symptom onset and last positive RT-PCR (days)	11 (3 to 15)	9 (8 to 10)	p=0.37	
			Proportion of CPE positive samples	42%	38%	NR	
Hirotsu (Hirotsu et al. 2021)	Japan, Feb-Sep 2021, Delta (100%)	Moderna, Pfizer	Mean viral load (log10 copies/ml)	6.0 (1.6)	6.5 (0.8)	NR	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Delta (100%)	Pfizer, Janssen, AstraZeneca, Moderna, Sputnik, Sinopharm	Mean Ct values	24.1 (6.4)	25.0 (6.7)	p<0.001	

Study	Country, time, dominant variant	Vaccine	Outcomes		Effect estimate		
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Kale (Kale et al. 2021)	India, Jan-May 2021, Delta (70%), Kappa (24%)	AstraZeneca	Median Ct values (unvaccinated = partially vaccinated)		21.1 (12.0 to 29.5)	23.2 (0.03 to 33.1)	p=0.82
Kang (Kang et al. 2022)	China, May-Jun 2021, Delta (100%)	NR	Predicted median Ct value, days after symptom onset	Day 0	24.5 (23.6 to 26.7)	25.5 (25.3 to 25.8)	NR
				Day 8	27.9 (27.3 to 30.5)	29.7 (29.3 to 30.3)	NR
				Day 16	34.6 (34.0 to 36.6)	36.1 (35.9 to 36.5)	NR
			Difference in Ct value		-	-	0.97 (0.19 to 1.76)
Kerwin (Kerwin et al. 2021)	US, Feb-Jul 2021, Delta (74%)	NR	Median Ct value		21 (17 to 25)	22 (17 to 26)	p=0.83
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Delta (100%)	Pfizer, Moderna	Mean Ct value		16.5 (4.9)	17.7 (5.7)	2.24 (0.85 to 3.64)
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AstraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values		18.5 (5.0)	18.1 (4.8)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: -0.002 (-0.6 to 0.6)
			Mean (standard deviation) Ct values for time since fully vaccinated	Completion < 113 days	-	18.9 (4.7)	Confounder-adjusted mean difference between Omicron and Delta: -0.7 (-1.13 to -0.28)
				Completion 113-168 days	-	18.0 (4.8)	Confounder-adjusted mean difference between Omicron and Delta: 0.13 (-0.14 to 0.39)



Study	Country, time, dominant variant	Vaccine	Outcomes		Effect estimate		
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
				Completion 169+ days	-	17.8 (4.9)	Confounder-adjusted mean difference between Omicron and Delta: 0.32 (-0.08 to 0.73)
Kissler (Kissler et al. 2021)	USA, November 28 2020 to August 11 2021	Pfizer/BioNTech	Vaccine breakthrough infection: Mean peak Ct		20.7 (19.8, 20.2)	20.5 (19.0, 21.0)	NR
		Johnson & Johnson/Janssen	Vaccine breakthrough infection: Mean proliferation time (days)		3.5 (3.0, 4.0)	3.2 (2.5, 4.0)	NR
		Moderna	Vaccine breakthrough infection: Mean viral clearance time (days)		7.5 (6.8, 8.2)	5.5 (4.6, 6.5)	NR
		NR vaccine	Vaccine breakthrough infection: Acute infection duration (days)		11.0 (10.3, 11.8)	8.7 (7.6, 9.9)	NR
Levine-Tiefenbrun (Levine-Tiefenbrun et al. 2021a)	Israel, Jun-Sep 2021, Delta (93%)	Pfizer	Mean Ct value	All	27.7 (5.0)	26.9 (5.0)	0.22 (0.02 to 0.42)
				7-30 days after 2 <sup>nd</sup> dose		31.2 (4.5)	4.56 (2.19 to 6.94)
				31-60 days after 2 <sup>nd</sup> dose		29.3 (5.1)	2.63 (0.67 to 4.59)
				61-120 days after 2 <sup>nd</sup> dose		27.2 (4.8)	0.58 (0.05 to 1.12)
				121-180 days after 2 <sup>nd</sup> dose		27.0 (5.0)	0.29 (0.08 to 0.51)
			>180 days after 2 <sup>nd</sup> dose	26.7 (5.0)	0.06 (-0.16 to 0.29)		
			Mean Ct value ( <i>unvaccinated</i> = 2 months after the second dose, <i>vaccinated</i> = 2-6 months after the second dose)		-	-	-3.1 (-4.6 to -1.6)
Levine-Tiefenbrun (Levine-Tiefenbrun et al. 2022)	Israel, Jun-Nov 2021, Delta (>93%)	Pfizer	Mean Ct values	7-30 days after 2 <sup>nd</sup> dose	26.8 (5.0)	30.8 (4.5)	NR
				31-60 days after 2 <sup>nd</sup> dose		28.4 (5.0)	NR
				61-120 days after 2 <sup>nd</sup> dose		27.2 (4.8)	NR
				121-180 days after 2 <sup>nd</sup> dose		26.9 (5.0)	NR
				>180 days after 2 <sup>nd</sup> dose		26.8 (5.0)	NR
Li (Li et al. 2021)	China, May-Jun 2021, Delta (100%)	Sinovac, Sinopharm	Proportion of Ct value <24 ( <i>vaccinated</i> = partially or fully vaccinated)		49.6%	44.7%	p=0.23
			Proportion of Ct value 24-40 ( <i>vaccinated</i> = partially or fully vaccinated)		36.5%	52.6%	
Luo (Luo et al. 2021a, Luo et al. 2021b) <sup>2</sup>	US, Jan-Jul 2021, Delta (100%)	Janssen, Moderna, Pfizer	Mean Ct value		21.1	20.2	NR
			Mean Ct ≤5 days after symptom onset		20.3	20.3	NR
			Mean Ct >5 days after symptom onset		24.6	21.1	NR
			Proportion of CPE positive samples		74.4%	76.6%	NR

Study	Country, time, dominant variant	Vaccine	Outcomes	Effect estimate		
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Lyngse (Lyngse et al. 2022b)	Denmark, Jun-Nov 2021, Delta	AstraZeneca, Janssen, Moderna, Pfizer	Mean Ct values	NR	NR	1.6
Magalis (Magalis et al. 2021)	US, Oct 2020-Aug 2021, Delta (100%)	Janssen, Moderna, Pfizer	Mean viral load (log <sub>10</sub> copies/ml)	7.36 (3.29 to 10.8)	4.66 (1.2 to 10.6)	p<0.00001
Miguères (Miguères et al. 2022)	France, July to September 2021, Delta (NR)	Pfizer, Moderna, AstraZeneca, Unknown, Janssen	Mean viral load (log <sub>10</sub> copies/ml) (IQR)	7.1 (5.7 to 7.9)	6.6 (5.4 to 7.5)	p < 0.0001
Pena-Hernandez (Peña-Hernández et al. 2022)	US, Jul-Aug 2021, Delta	Moderna, Pfizer	Proportion of CPE positive samples	40%	21%	RR=0.49 (0.27 to 0.91)
Pouwels (Pouwels et al. 2021)	UK, May-Jun 2021, Delta (>61%)	Pfizer or AstraZeneca	Median Ct value (seronegative)	21.5 (16.4 to 31.7)	32.3 (26.0 to 34.0)	NR
	UK, Jun-Aug 2021, Delta (>92%)			25.7 (19.1 to 30.8)	25.3 (19.1 to 31.3)	p=0.35
Puhach (Puhach et al. 2022)	Switzerland, Apr 2020-Dec 2021, Delta	Pfizer, Moderna, CoviVac, other	Ct value (E gene)	13.8 to 26.3	16.3 to 26.1	NR
			Proportion of CPE positive samples	91.7%	83.8%	NR
			CPE positive samples at 5 days after symptom onset	84.6%	53.8%	NR
Riemersma (Riemersma et al. 2021)	US, Jun-Jul 2021, Delta (69% to 95%)	mRNA or adenovirus vaccines	Mean Ct value (N1)	23.3 (5.6)	22.8 (5.9)	p=0.23
			Mean Ct value (N1, symptomatic)	22.9 (5.5)	22.6 (5.8)	p=0.74
			Mean Ct value (N1, asymptomatic)	27.0 (5.6)	26.1 (7.1)	p=0.05
			Proportion of CPE positive samples	88.2%	94.9%	NR
Salvatore (Salvatore et al. 2021)	US, Jul-Aug 2021, Delta	Janssen, Moderna, Pfizer	Median Ct value (day 1 of symptom onset or first positive test)	28.5 (24.8 to 31.8)	26.4 (23.5 to 28.4)	p>0.0026
			Median Ct value (day 10 after symptom onset or positive test)	34.5 (29.4 to 35.2)	32.9 (30.5 to 34.6)	p>0.0026
			Proportion of CPE positive samples	12%	8%	p=0.16
			Median duration of RT-PCR positivity	12 days	13 days	NR
			Median duration of viral culture	5 days	5 days	p=0.29
Servellita (Servellita et al. 2022)	US, Feb-Jun 2021, Delta (100%)	Moderna, Pfizer, Janssen	Mean Ct value (N gene)	19.5	21.5	p=0.09

Siddle (Siddle et al. 2022)	US, Jul-Aug 2021, Delta (99%)	Janssen, Moderna, Pfizer	Mean Ct values (asymptomatic)	24.1 (2.25)	24.0 (6.0)	NR
			Mean Ct values (symptomatic)	24.3 (6.7)	24.4 (6.1)	NR

Study	Country, time, dominant variant	Vaccine	Outcome		Effect estimate			
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta (100%)	AstraZeneca, Pfizer	Median viral load growth rate per day (ORF1ab gene) <sup>4</sup>		4.16 (2.19 to 11.8)	4.43 (3.01 to 10.2)	NR	
			Median viral load decline rate per day (ORF1ab gene) <sup>4</sup>		1.81 (1.52 to 2.2)	2.18 (1.88 to 2.57)	NR	
			Median peak log <sub>10</sub> viral load per ml (ORF1ab gene) <sup>4</sup>		8.09 (7.74 to 8.42)	8.19 (7.99 to 8.41)	NR	
Sriraman (Sriraman et al. 2022)	India, July – Sept 2021, Delta (NR)	Covaxin (Bharat Biotech) and AstraZeneca	Proportion expelling virus (within 48 hours of COVID-19 diagnosis)	AstraZeneca	92%	93%	NR	
				Covaxin		96%		
			Proportion expelling virus (8 – 12 days since diagnosis)	AstraZeneca	58%	62%	NR	
				Covaxin		90%		
			Median Ct value (IQR) within 48 hours of diagnosis	AstraZeneca	Nasopharyngeal sample	Nasopharyngeal: 27 (21 to 33) Mask: 34 (29 to 36)	21 (17 to 27)	p = 0.123
					Mask sample		31 (27 to 34)	p = 0.213
				Covaxin	Nasopharyngeal sample		23 (22 to 26)	p = 0.123
					Mask sample		31 (27 to 35)	p = 0.213
			Median Ct value (IQR) within 8 – 12 days since diagnosis	AstraZeneca	Nasopharyngeal sample	Nasopharyngeal: 27 (25 to 35) Mask: 37 (31 to 39)	32 (28 to 36)	p = 0.237
					Mask sample		35 (34 to 37)	p = 0.398
Covaxin	Nasopharyngeal sample	33 (29 to 36)		p = 0.237				
	Mask sample	34 (32 to 37)		p = 0.398				
Yi (Yi et al. 2022)	South Korea, Aug 2021, Delta (100%)	Moderna, Pfizer	Mean Ct values (asymptomatic)		17.2	Nasopharyngeal sample	NR	
			Mean Ct values (symptomatic)		15.1	20	NR	

Study	Country, time, dominant variant	Vaccine	Outcome		Effect estimate			
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
<b>Partially vaccinated, Delta variant</b>								
Elliott (Elliott et al. 2021)	UK, Jun-Jul 2021, <b>Delta</b> (100%)	NR	Median Ct value		23.1 (20.3 to 25.8)	27.4 (24.8 to 30.0)	p=0.04	
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, <b>Delta</b> (100%)	Pfizer	Proportion of reduction in transmission mediated via index case Ct values at diagnosis		-	-	12% (7% to 19%)	
		AstraZeneca			-	-	14% (11% to 17%)	
Griffin (Griffin et al. 2021)	US, May-Jul 2021, <b>Delta</b> (>90%)	Janssen, Moderna, Pfizer	Median Ct value ( <i>ORF1ab</i> gene)		18.8	17.8	p>0.05	
			Median Ct value ( <i>N</i> gene)		19.3	18.6		
			Median Ct value ( <i>SC2N</i> gene)		19.3	20.2		
Hirotsu (Hirotsu et al. 2021)	Japan, Feb-Sep 2021, <b>Delta</b> (100%)	Moderna, Pfizer	Mean viral load (log <sub>10</sub> copies/ml)		6.0 (1.6)	5.5 (2.2)	NR	
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, <b>Delta</b> (100%)	Pfizer, Moderna	Mean Ct value		16.5 (4.9)	16.1 (5.0)	-0.15 (-0.99 to 0.96)	
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially <b>Delta</b> , but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AstraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values		18.5 (5.0)	19.5 (5.7)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: -0.002(-0.6 to 0.6)	
Miguères (Miguères et al. 2022)	France, July to September 2021, <b>Delta (NR)</b>	Pfizer, Moderna, AstraZeneca. Unknown, Janssen	Mean viral load (log <sub>10</sub> copies/ml) (IQR)		7.1 (5.7 to 7.9)	7 (5.6 to 7.8)	NR	
Pouwels (Pouwels et al. 2021)	UK, May-Jun 2021, <b>Delta</b> (>61%)	Pfizer, AstraZeneca	Median Ct value (seronegative)		21.5 (16.4 to 31.7)	30.1 (26.0 to 34.0)	NR	
	UK, Jun-Aug 2021, <b>Delta</b> (>92%)				25.7 (19.1 to 30.8)	24.7 (18.8 to 31.3)	NR	
Sriraman (Sriraman et al. 2022)	India, July – Sept 2021, <b>Delta (NR)</b>	Covaxin (Bharat Biotech) and AstraZeneca	Proportion expelling virus (within 48 hours of COVID-19 diagnosis)		AstraZeneca	96%	NR	
					Covaxin		92%	NR
			Proportion expelling virus (8 – 12 days since diagnosis)		AstraZeneca	58%	52%	NR
					Covaxin		NR	NR
			Median Ct value (IQR) within 48 hours of diagnosis	AstraZeneca	Nasopharyngeal sample	Nasopharyngeal: 27 (21 to 33) Mask: 34 (29 to 36)	26 (22 to 28)	p = 0.123
					Mask sample		33 (30 to 36)	p = 0.213
Covaxin	Nasopharyngeal sample	17			p = 0.123			
	Mask sample	26			p = 0.213			

Study	Country, time, dominant variant	Vaccine	Outcome		Effect estimate			
					Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
			Median Ct value (IQR) within 8 – 12 days since diagnosis	AstraZeneca	Nasopharyngeal sample	Nasopharyngeal: 27 (25 to 35) Mask: 37 (31 to 39)	33 (31 to 37)	p = 0.237
					Mask sample		35 (32 to 37)	p = 0.398
				Covaxin	Nasopharyngeal sample		Not detected	p = 0.237
					Mask sample		37	p = 0.398
<b>Fully vaccinated, pre-Delta variant</b>								
Adamson (Adamson et al. 2021)	US, Dec 2020-Mar 2021, NR	Janssen, Moderna, Pfizer	Median Ct value		20.1 (16.9 to 25.1)	30.4 (20.8 to 34.1)	NR	
Abu-Raddad (Abu-Raddad et al. 2022)	Qatar, Feb 2020-Jul 2021, <b>Wild-type, Alpha, Beta</b>	Pfizer	Mean Ct value		24.0 (6.5)	25.0 (6.6)	1.0 (0.7 to 1.2)	
			Mean Ct value (symptomatic)		22.5 (6.0)	22.7 (6.0)	0.2 (-0.2 to 0.6)	
			Mean Ct value (asymptomatic)		25.5 (6.6)	26.8 (6.5)	1.3 (0.9 to 1.8)	
		Moderna	Mean Ct value		26.8 (7.1)	30.3 (5.9)	3.5 (2.4 to 4.6)	
			Mean Ct value (symptomatic)		21.7 (5.5)	26.6 (6.7)	4.9 (2.4 to 7.4)	
Mean Ct value (asymptomatic)		28.0 (6.7)	31.2 (5.5)	3.2 (1.8 to 4.5)				
Bailly (Bailly et al. 2022)	France, Mar 2021, <b>Beta</b>	Pfizer	Mean Ct value		15	21	p<0.05	
Blanquart (Blanquart et al. 2021)	France, Jun-Jul 2021, <b>non-Delta</b> (100%)	NR	Difference in Ct value (symptomatic)		-	-	-1.91 (-5.99 to 2.16)	
			Difference in Ct value (asymptomatic)		-	-	4.07 (1.84 to 6.31)	
Boschi (Boschi et al. 2021)	France, Jan-July 2021, Alpha and Delta (percentages NR)	AstraZeneca, Janssen, Moderna, Pfizer	Mean Ct value		21.5 (4.5)	23.4 (5.4)	NR	
			Proportion of CPE positive samples		80%	66%	p<0.0001	
Brunner-Ziegler (Brunner-Ziegler et al. 2022)	Austria, Jan-Jul 2021, Alpha (81%)	AstraZeneca, Pfizer	Mean Ct value		22.6 (7.1)	24.8 (6.4)	NR	
Costa (Costa et al. 2022)	Spain, Feb-Jul 2021, Alpha (54%), Delta (46%)	AstraZeneca, Janssen, Pfizer	Mean viral load (log10 copies/ml)	All	8.1	7.8	p=0.31	
				Asymptomatic	8.4	8.7	p=0.85	
				Symptomatic	8.1	7.4	p=0.12	
Emary (Emary et al. 2021)	UK, May 2020-Jan 2021, <b>Alpha</b> (100%)	AstraZeneca	Median Ct value		15.2 (13.0 to 19.3)	19.3 (15.4 to 22.0)	p=0.026	
	UK, May 2020-Jan 2021, <b>Alpha</b> (35%), <b>Wild-type</b> (65%)		Median Ct value		20.2 (15.5 to 29.6)	28.8 (20.5 to 33.5)	p<0.0001	
			Median Ct value (symptomatic)		17.9 (15.0 to 25.1)	20.6 (15.4 to 24.5)	p=0.07	
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, <b>Alpha</b> (100%)	AstraZeneca	Median Ct value (symptomatic)		18.4 (15.7 to 22.5)	23.9 (18.1 to 32.5)	NR	

Study	Country, time, dominant variant	Vaccine	Outcome	Effect estimate		
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
		Pfizer		18.4 (15.7 to 22.5)	27.4 (19.7 to 32.1)	NR
		AstraZeneca	Proportion of reduction in transmission mediated via index case Ct values at diagnosis	-	-	18% (9% to 64%)
		Pfizer		-	-	16% (1% to 80%)
Griffin (Griffin et al. 2021)	US, May-Jul 2021, <b>Alpha</b> (>50%)	Janssen, Moderna, Pfizer	Median Ct value ( <i>ORF1ab</i> gene)	22.8	27.2	p<0.05
			Median Ct value ( <i>N</i> gene)	24.0	30.6	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Alpha (100%)	Pfizer, Janssen, AstraZeneca, Moderna, Sputnik, Sinopharm	Mean Ct values	26.9 (6.4)	33.1 (6.0)	p<0.001
Ioannou (Ioannou et al. 2021)	Greece, Jan-Apr 2021, <b>Alpha</b> (98%)	Pfizer	Median Ct value	18.5 (13.5 to 24)	18.5 (16 to 26)	p=0.70
Jacobson (Jacobson et al. 2022)	US, Dec-Apr 2021, <b>L452R</b> (39.5%)	Pfizer, Moderna	Mean Ct value	23.0 (7.4)	28.5 (7.4)	NR
			Mean Ct value ( <i>unvaccinated</i> = unvaccinated/early post-vaccination, <i>vaccinated</i> = fully/partially vaccinated)	22.9	27.9	p<0.001
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, <b>Alpha</b> (100%)	Pfizer, Moderna	Mean Ct value	18.4 (5.2)	21.8 (5.7)	4.49 (2.07 to 6.91)
Kolobukhina (Kolobukhina et al. 2021)	Russia, Dec 2020-Apr 2021, NR	Sputnik V	Mean Ct value	31.5 (27.2 to 33.7)	34.8 (31.4 to 36.5)	p=0.026
Lumley (Lumley et al. 2021)	UK, Mar 2020-Feb 2021, <b>Alpha</b> (56%)	AstraZeneca, Pfizer	Median Ct value (seronegative)	18.3 (14.0 to 25.5)	19.7 (15.0 to 27.5)	2.7 (-0.5 to 6.8)
			Median Ct value (seropositive)	27.2 (18.8 to 32.2)	-	-
Luo (Luo et al. 2021a, Luo et al. 2021b) <sup>2</sup>	US, Jan-Jul 2021, <b>Alpha</b> (100%)	Pfizer, Moderna, Janssen	Mean Ct values	21.7	22.7	NR
			Mean Ct values ≤5 days after symptom onset	21.3	21.5	NR
			Mean Ct values >5 days after symptom onset	24.6	24.2	NR
			Proportion of CPE positive samples	37.9%	17.4%	p=0.02
Magalis (Magalis et al. 2021)	US, Oct 2020-Aug 2021, non-Delta	Janssen, Moderna, Pfizer	Mean viral load (log10 copies/ml)	6.15 (3.56 to 10.9)	5.39 (1.41 to 8.36)	p<0.00001
McEllistrem (McEllistrem et al. 2021)	US, Dec 2020-Feb 2021, <b>NR</b>	Pfizer	Median Ct value	12.8 (12.4 to 14.9)	19.4 (18.9 to 25.5)	p=0.009
			Mean log <sub>10</sub> viral load	9.5 (9.3 to 9.8)	7.1 (5.4 to 8.8)	-2.4 (p=0.004)
Mostafa (Mostafa et al. 2021)	US, Jan-May 2021, <b>Alpha</b> (61%), <b>Iota</b> (13.5%)	Pfizer, Moderna	Median Ct value ( <i>N</i> gene)	19.6 (16.3 to 22.8)	19.2 (16.6 to 22.0)	NR
			Proportion of CPE positive samples	64.5%	18.5%	p<0.00001

Study	Country, time, dominant variant	Vaccine	Outcome	Effect estimate			
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Muhsen (Muhsen et al. 2021)	Israel, Jan-Apr 2021, <b>Alpha</b> (dominant)	Pfizer	Median Ct value ( <i>ORF1ab</i> gene)	26.7 (28.7 to 33.5)	32.0 (22.9 to 31.0)	p=0.008	
Pajon (Pajon et al. 2021)	US, Jul 2020-Mar 2021, <b>Wild-type (B.1/B.1.2)</b> (93%)	Moderna	Median time to viral clearance (days)	7	4	3	
			Estimated Ct values (symptomatic), days after symptoms	Day 1	20.26	27.27	7.01 (4.74 to 9.28)
				Day 3	31.80	37.63	5.84 (3.03 to 8.64)
				Day 5	34.07	39.87	5.80 (1.73 to 8.37)
				Day 7	35.23	39.37	4.13 (1.73 to 6.54)
Day 28	40.73	41.03	0.30 (-0.33 to 0.90)				
Pouwels (Pouwels et al. 2021)	UK, Dec 2020-May 2021, <b>Alpha</b> (dominant)	Pfizer, AstraZeneca	Median Ct value (seronegative)	28.7 (20.4 to 32.9)	33.3 (31.6 to 34.0)	p=0.02	
			p value for trend (increasing Ct value with time from first vaccination and number of doses)	-	-	p<0.0001	
Regev-Yochay (Regev-Yochay et al. 2021)	Israel, Dec 2020-Mar 2021, <b>NR</b>	Pfizer	Mean Ct value	22.2 (1.0)	27.3 (1.2)	5.09 (2.8 to 7.4)	
			Median Ct value	23.3	25.8	p<0.001	
Servellita (Servellita et al. 2022)	US, Feb-Jun 2021, <b>All</b>	Moderna, Pfizer, Janssen	Mean Ct value ( <i>N</i> gene)	23.1	23.1	p=0.99	
			Mean Ct value ( <i>N</i> gene, symptomatic)	21.9	21.2	p=0.64	
			Mean Ct value ( <i>N</i> gene, asymptomatic)	24.6	30.1	p=0.023	
	US, Feb-Jun 2021, <b>Alpha</b> (100%)		Mean Ct value ( <i>N</i> gene)	21.5	22.1	p=0.70	
	US, Feb-Jun 2021, <b>Beta</b> (100%)			22.8	26.5	p=0.27	
	US, Feb-Jun 2021, <b>Gamma</b> (100%)			19.8	20.2	p=0.78	
	US, Feb-Jun 2021, <b>Epsilon</b> (100%)			21.0	24.3	p=0.15	
US, Feb-Jun 2021, <b>Iota</b> (100%)	21.8	20.9	p=0.64				
US, Feb-Jun 2021, <b>Other</b> (100%)	22.3	23.8	p=0.45				
Smith (Smith et al. 2022)	Worldwide, Mar 2020-Nov 2021, Non-Delta (100%)	NR	Mean viral load (log10 PFU/ml)	3.2	3.1	NR	
Tande (Tande et al. 2021)	US, Dec 2020-Feb 2021, NR	Pfizer, Moderna	Mean Ct value (asymptomatic)	Arizona (Alinity instrument)	26.6 (8.3)	30.0 (6.1)	NR
				Arizona (m2000 instrument)	15.1 (7.7)	18.6 (9.3)	NR

Study	Country, time, dominant variant	Vaccine	Outcome	Effect estimate		
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Thompson (Thompson et al. 2021)	US, Dec 2020-Apr 2021, Wild-type (70% to 90%)	Pfizer (67%), Moderna (33%)	Mean log10 viral copies/μL (vaccinated = partial or full vaccination)	3.8 (1.7)	2.3 (1.7)	40.2% (16.3% to 57.3%) <sup>1</sup>
			Mean days of viral RNA detection (vaccinated = partial or full vaccination)	8.9 (10.2)	2.7 (3.0)	6.2 (4.0 to 8.4)
			Mean days spent in sick bed (vaccinated = partial or full vaccination)	3.8 (5.9)	1.5 (2.1)	2.3 (0.8 to 3.7)
Williams (Williams et al. 2021)	UK, March to April 2021, Alpha	NR	Mean Ct value	25.55	25.42	NR
<b>Partially vaccinated, pre-Delta variant</b>						
Brunner-Ziegler (Brunner-Ziegler et al. 2022)	Austria, Jan-Jul 2021, Alpha (81%)	AstraZeneca, Pfizer	Mean Ct value	22.6 (7.1)	25.5 (7.4)	NR
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, Alpha (100%)	Pfizer	Proportion of reduction in transmission mediated via index case Ct values at diagnosis	-	-	33% (23% to 53%)
		AstraZeneca		-	-	39% (30% to 50%)
Griffin (Griffin et al. 2021)	US, May-Jul 2021, Alpha (>50%)	Janssen, Moderna, Pfizer	Median Ct value ( <i>ORF1ab</i> )	22.8	36.6	p<0.05
			Median Ct value ( <i>N</i> )	24.0	36.0	
Jacobson (Jacobson et al. 2022)	US, Dec-Apr 2021, L452R (39.5%)	Pfizer, Moderna	Mean Ct value	23.0 (7.4)	27.7 (8.7)	NR
Jones (Jones et al. 2021)	UK, Jan 2021, Alpha	Pfizer	Median Ct value	23.4 (13.5 to 33.0)	30.3 (25.5 to 35.1)	p>0.05
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Alpha (100%)	Pfizer, Moderna	Mean Ct value	18.4 (5.2)	20.0 (5.6)	1.87 (0.2 to 3.53)
Levine-Tiefenburn (Levine-Tiefenburn et al. 2021b)	Israel, Dec 2020-Feb 2021, NR	Pfizer	Mean Ct value ( <i>RdRp</i> ), days post-vaccination	1-11 days	-	-0.07 (-0.19 to 0.06)
				12-21 days	-	1.75 (1.60 to 1.91)
				22-37 days	-	2.15 (1.87 to 2.42)
Pouwels (Pouwels et al. 2021)	UK, Dec 2020-May 2021, Alpha (dominant)	Pfizer, AstraZeneca	Median Ct value (seronegative)	28.7 (20.4 to 32.9)	31.6 (26.6 to 33.7)	NR
Shrotri (Shrotri et al. 2021)	UK, Dec 2020-Mar 2021, Alpha	AstraZeneca (67%), Pfizer (33%)	Mean Ct value	26.6 (6.6)	31.3 (8.7)	p<0.0001
Tande (Tande et al. 2021)	US, Dec 2020-Feb 2021, NR	Pfizer (94%), Moderna (5.9%)	Mean Ct value (asymptomatic)	26.6 (8.3)	30.5 (6.1)	NR
			Arizona (Alinity instrument)			



Study	Country, time, dominant variant	Vaccine	Outcome	Effect estimate		
				Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
			Arizona (m2000 instrument)	15.1 (7.7)	11.1 (7.1)	NR
			Rochester	30.4 (4.4)	30.9 (-)	NR

*CI = confidence interval, CPE = cytopathic effect (i.e. infectious virus), HYT = Healthy Yolo Together (testing centre), RR = relative risk, UeS = Unidos en Salud (testing centre)*

*\*When a difference is not reported, a p-value presented instead if reported; <sup>1</sup>Relative difference; <sup>2</sup>Updated from previous report (pre-print was published or updated); <sup>3</sup>As reported in paper;*

*<sup>4</sup>2.5% and 97.5% centiles reported <sup>5</sup>data extracted from figure*

The studies included people who had received COVID-19 booster vaccinations (three doses), those who were fully vaccinated (two doses), those who were partially vaccinated (one dose), and those who were unvaccinated (no vaccine doses).

*Studies with black text are from this updated search; studies with grey text are from a previous search*

## 9. References

Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. (2022). Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. *Nature Communications*. 13(1): 532. doi: <https://dx.doi.org/10.1038/s41467-022-28199-7>

Academy of Nutrition and Dietetics. (2016). Evidence analysis manual: steps in the Academy evidence analysis process. Available at: <https://www.andeal.org/evidence-analysis-manual> [Accessed 24 May 2022].

Accorsi EK, Britton A, Fleming-Dutra KE, et al. (2022). Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*. 327(7): 639-51. doi: <https://dx.doi.org/10.1001/jama.2022.0470>

Acharya CB, Schrom J, Mitchell AM, et al. (2021). No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups when infected with SARS-CoV-2 Delta variant. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.09.28.21264262>

Adamson PC, Pfeffer MA, Arboleda VA, et al. (2021). Lower Severe Acute Respiratory Syndrome Coronavirus 2 viral shedding following coronavirus disease 2019 vaccination among healthcare workers in Los Angeles, California. *Open Forum Infectious Diseases*. 8(11): ofab526. doi: <https://doi.org/10.1093/ofid/ofab526>

Allen H, Tessier E, Turner C, et al. (2022a). Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. *MedRxiv*. [Pre-print]: 2022.02.15.22271001. doi: <https://doi.org/10.1101/2022.02.15.22271001>

Allen H, Vusirikala A, Flannagan J, et al. (2022b). Household transmission of COVID-19 cases associated with SARS-CoV-2 Delta variant (B.1.617.2): national case-control study. *Lancet Regional Health Europe*. 12: 100252. doi: <https://doi.org/10.1016/j.lanepe.2021.100252>

Allen H, Vusirikala A, Flannagan J, et al. (2021). Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case control study. *PHE Publishing*. [Pre-print]. doi: <https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa>

Andrejko KL, Pry J, Myers JF, et al. (2021). Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 infection following high-risk exposure. *Clinical Infectious Diseases*. [Article-in-press]: ciab1040. doi: <https://doi.org/10.1093/cid/ciab1040>

Bailly B, Guilpain L, Bouiller K, et al. (2022). BNT162b2 messenger RNA vaccination did not prevent an outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. *Clinical Infectious Diseases*. 74(3): 517-20. doi: <https://doi.org/10.1093/cid/ciab446>

Barbosa G, Chaves APC, de Souza Luna L, et al. (2022). SARS-CoV-2 breakthrough infection and viral load among healthcare workers after COVID-19 vaccines. *Journal of Medical Virology*. 94(6): 2350-1. doi: <https://dx.doi.org/10.1002/jmv.27639>

Blanquart F, Abad C, Ambroise J, et al. (2021). Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. *Euro Surveill*. 26(37): 2100824. doi: <https://doi.org/10.2807/1560-7917.ES.2021.26.37.2100824>

Bobdey S, Kaushik SK, Sahu R, et al. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine: experience of a tertiary care institute. *Medical Journal Armed Forces India*. 77(Supplement 2): S271-7. doi: <https://doi.org/10.1016/j.mjafi.2021.06.006>

Bordas A, Soriano-Arandes A, Subirana M, et al. (2022). Study protocol for monitoring SARS-CoV-2 infection and its determinants in Catalonia (Spain): an observational and participatory research approach in a Sentinel Network of Schools. *BMJ Open*. 12(1): e055649. doi: <https://dx.doi.org/10.1136/bmjopen-2021-055649>

Boschi C, Aherfi S, Houhamdi L, et al. (2021). Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status. *Emerging Microbes & Infections*. 10(1): 2276-8. doi: <https://doi.org/10.1080/22221751.2021.2008776>

Boucau J, Marino C, Regan J, et al. (2022). Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. *MedRxiv*. [Pre-print]. doi: <https://dx.doi.org/10.1101/2022.03.01.22271582>

Braeye T, Cornelissen L, Catteau L, et al. (2021). Vaccine effectiveness against infection and onwards transmission of COVID-19: analysis of Belgian contact tracing data, January-June 2021. *Vaccine*. 39(39): 5456-60. doi: <https://doi.org/10.1016/j.vaccine.2021.08.060>

Brandal LT, MacDonald E, Veneti L, et al. (2021). Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro Surveill*. 26(50): 2101147. doi: <https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2101147>

Brunner-Ziegler S, Spath T, Kornek G, et al. (2022). Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. *Clinical Microbiology and Infection*. 28(4): 596-601. doi: <https://dx.doi.org/10.1016/j.cmi.2021.11.023>

Chia PY, Xiang Ong SW, Chiew CJ, et al. (2021). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.07.28.21261295>

Christensen PA, Olsen RJ, Long SW, et al. (2022). Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. *American Journal of Pathology*. 192(2): 320-31. doi: <https://dx.doi.org/10.1016/j.ajpath.2021.10.019>

Clifford S, Waight P, Hackman J, et al. (2021). Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.11.24.21266401>

Costa R, Olea B, Bracho MA, et al. (2022). RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. *Journal of Infection*. 84(4): 579-613. doi: <https://dx.doi.org/10.1016/j.jinf.2021.12.018>

de Gier B, Andeweg S, Backer J, et al. (2021a). Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.10.14.21264959>

de Gier B, Andeweg S, Joosten R, et al. (2021b). Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro Surveill. 26(31): 2100640. doi: <https://dx.doi.org/10.2807/1560-7917.ES.2021.26.31.2100640>

Elliott P, Haw D, Wang H, et al. (2021). REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021. Imperial College London. [Pre-print]. doi: <http://hdl.handle.net/10044/1/90800>

Emary KRW, Golubchik T, Aley PK, et al. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 397(10282): 1351-62. doi: [https://dx.doi.org/10.1016/S0140-6736\(21\)00628-0](https://dx.doi.org/10.1016/S0140-6736(21)00628-0)

Eyre DW, Taylor D, Purver M, et al. (2022). Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. New England Journal of Medicine. 386(8): 744-56. doi: <https://dx.doi.org/10.1056/NEJMoa2116597>

Fall A, Eldesouki RE, Sachithanandham J, et al. (2022). A quick displacement of the SARS-CoV-2 variant Delta with Omicron: unprecedented spike in COVID-19 cases associated with fewer admissions and comparable upper respiratory viral loads. MedRxiv. [Pre-print]. doi: <https://dx.doi.org/10.1101/2022.01.26.22269927>

Gazit S, Mizrahi B, Kalkstein N, et al. (2021a). BNT162b2 mRNA vaccine effectiveness given confirmed exposure: analysis of household members of coronavirus disease 2019 patients. Clinical Infectious Diseases. [Article-in-press]: ciab973. doi: <https://doi.org/10.1093/cid/ciab973>

Gazit S, Mizrahi B, Kalkstein N, et al. (2021b). BNT162b2 mRNA vaccine effectiveness given confirmed exposure; analysis of household members of COVID-19 patients. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.06.29.21259579>

Griffin JB, Haddix M, Danza P, et al. (2021). SARS-CoV-2 infections and hospitalizations among persons aged  $\geq 16$  years, by vaccination status - Los Angeles County, California, May 1-July 25, 2021. Morbidity and Mortality Weekly Report. 70(34): 1170-6. doi: <https://doi.org/10.15585/mmwr.mm7034e5>

Hagan LM, McCormick DW, Lee C, et al. (2021). Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant infections among incarcerated persons in a federal prison - Texas, July-August 2021. Morbidity and Mortality Weekly Report. 70(38): 1349-54. doi: <https://doi.org/10.15585/mmwr.mm7038e3>

Harris RJ, Hall JA, Zaidi A, et al. (2021a). Effect of vaccination on household transmission of SARS-CoV-2 in England. New England Journal of Medicine. 385(8): 759-60. doi: <https://doi.org/10.1056/NEJMc2107717>

Harris RJ, Hall JA, Zaidi A, et al. (2021b). Impact of vaccination on household transmission of SARS-COV-2 in England. PHE Publishing. [Pre-print]. doi: <https://khub.net/documents/135939561/390853656/Impact+of+vaccination+on+household+transmission>

[+of+SARS-COV-2+in+England.pdf/35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a?version=1.1&t=1619601878136&download=true](#)

Hirotsu Y, Tsutsui T, Kakizaki Y, et al. (2021). Active immunization by COVID-19 mRNA vaccine results in rapid antibody response and virus reduction in breakthrough infection by Delta (B.1.617.2). Research Square. [Pre-print]. doi: <https://doi.org/10.21203/rs.3.rs-957198/v1>

Hsu L, Grüne B, Buess M, et al. (2021). COVID-19 breakthrough infections and transmission risk: real-world data analyses from Germany's largest public health department (Cologne). Vaccines (Basel). 9(11): 1267. doi: <https://doi.org/10.3390/vaccines9111267>

Ioannou P, Karakonstantis S, Astrinaki E, et al. (2021). Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. Infectious Diseases. 53(11): 876-9. doi: <https://doi.org/10.1080/23744235.2021.1945139>

Jacobson KB, Pinsky BA, Montez Rath ME, et al. (2022). Post-vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections and incidence of the presumptive B.1.427/B.1.429 variant among healthcare personnel at a Northern California academic medical center. Clinical Infectious Diseases. 74(5): 821-8. doi: <https://doi.org/10.1093/cid/ciab554>

Jalali N, Brustad HK, Frigessi A, et al. (2022). Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. MedRxiv. [Pre-print] doi: <https://doi.org/10.1101/2022.02.07.22270437>

Jones NK, Rivett L, Seaman S, et al. (2021). Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 10: e68808. doi: <https://doi.org/10.7554/eLife.68808>

Kale P, Gupta E, Bihari C, et al. (2021). Vaccine breakthrough infections by SARS-CoV-2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. Vaccines (Basel). 10(1): 54. doi: <https://doi.org/10.3390/vaccines10010054>

Kang M, Xin H, Yuan J, et al. (2022). Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. Euro Surveillance. 27(10): 2100815. doi: <https://dx.doi.org/10.2807/1560-7917.ES.2022.27.10.2100815>

Kerwin H, Briggs R, Nair-Desai S, et al. (2021). An analysis of SARS-CoV-2 vaccine breakthrough infections and associated clinical outcomes. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.09.09.21262448>

Kislaya I, Peralta Santos A, Borges V, et al. (2022a). Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. MedRxiv. [Pre-print] doi: <https://doi.org/10.1101/2022.01.31.22270200>

Kislaya I, Rodrigues EF, Borges V, et al. (2022b). Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. Emerging Infectious Diseases. 28(2): 331-7. doi: <https://dx.doi.org/10.3201/eid2802.211789>

Kissler SM, Fauver JR, Mack C, et al. (2021). Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. *New England Journal of Medicine*. 385(26): 2489-91. doi: <https://dx.doi.org/10.1056/NEJMc2102507>

Kolobukhina L, Burgasova O, Kruzhkova I, et al. (2021). Assessment of COVID-19 clinical course in patients vaccinated with Spitznik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity. *Bulletin of RSMU*. (5): 62-70. doi: <https://doi.org/10.24075/brsmu.2021.046>

Layan M, Gilboa M, Gonen T, et al. (2022). Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. *American Journal of Epidemiology*. [Article-in-press]: kwac042. doi: <https://dx.doi.org/10.1093/aje/kwac042>

Levine-Tiefenbrun M, Yelin I, Alapi H, et al. (2022). Waning of SARS-CoV-2 booster viral-load reduction effectiveness. *Nature Communications*. 13(1): 1237. doi: <https://dx.doi.org/10.1038/s41467-022-28936-y>

Levine-Tiefenbrun M, Yelin I, Alapi H, et al. (2021a). Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. *Nature Medicine*. 27(12): 2108-10. doi: <https://doi.org/10.1038/s41591-021-01575-4>

Levine-Tiefenbrun M, Yelin I, Katz R, et al. (2021b). Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nature Medicine*. 27(5): 790-2. doi: <https://dx.doi.org/10.1038/s41591-021-01316-7>

Li XN, Huang Y, Wang W, et al. (2021). Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. *Emerging Microbes & Infections*. 10(1): 1751-9. doi: <https://doi.org/10.1080/22221751.2021.1969291>

Lumley S, Rodger G, Constantinides B, et al. (2021). An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.03.09.21253218>

Luo CH, Morris CP, Sachithanandham J, et al. (2021a). Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha variant in both unvaccinated and vaccinated individuals. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.08.15.21262077>

Luo CH, Morris CP, Sachithanandham J, et al. (2021b). Infection with the SARS-CoV-2 Delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals. *Clinical Infectious Diseases*. [Article-in-press]: ciab986. doi: <https://doi.org/10.1093/cid/ciab986>

Lyngse FP, Kirkeby CT, Denwood M, et al. (2022a). Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. *MedRxiv*. [Pre-print]. doi: <https://dx.doi.org/10.1101/2022.01.28.22270044>

Lyngse FP, Mølbak K, Denwood M, et al. (2022b). Effect of vaccination on household transmission of SARS-CoV-2 Delta VOC. *MedRxiv*. [Pre-print]. doi: <https://dx.doi.org/10.1101/2022.01.06.22268841>

Lyngse FP, Mortensen LH, Denwood MJ, et al. (2021). SARS-CoV-2 Omicron VOC transmission in Danish households. *MedRxiv*. [Pre-print]. doi: <https://dx.doi.org/10.1101/2021.12.27.21268278>

Magalis BR, Rich S, Tagliamonte MS, et al. (2021). SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua, Florida. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.11.10.21266134>

Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. (2021). Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveillance. 26(39): 2100894. doi: <https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894>

McEllistrem MC, Clancy CJ, Buehrle DJ, et al. (2021). Single dose of a mRNA Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases. 73(6): e1365-7. doi: <https://dx.doi.org/10.1093/cid/ciab263>

Meyer E, Sandfort M, Bender J, et al. (2021). Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-March 2021. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.09.13.21262519>

Migueres M, Dimeglio C, Trémeaux P, et al. (2022). Influence of the Delta variant and vaccination on the SARS-CoV-2 viral load. Viruses. 14(2): 323. doi: <https://dx.doi.org/10.3390/v14020323>

Mostafa HH, Luo CH, Morris CP, et al. (2021). SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.07.05.21259105>

Muhsen K, Maimon N, Mizrahi A, et al. (2021). Effectiveness of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine against acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among healthcare workers in long-term care facilities: a prospective cohort study. Clinical Infectious Diseases. [Article-in-press]: ciab918. doi: <https://doi.org/10.1093/cid/ciab918>

Ng OT, Koh V, Chiew CJ, et al. (2021). Impact of Delta variant and vaccination on SARS-CoV-2 secondary attack rate among household close contacts. Lancet Regional Health West Pacific. 17: 100299. doi: <https://doi.org/10.1016/j.lanwpc.2021.100299>

Page MJ, McKenzie JE, Bossuyt PM, et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372: n71. doi: <https://doi.org/10.1136/bmj.n71>

Pajon R, Paila YD, Girard B, et al. (2021). Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 phase 3 COVE trial. MedRxiv. [Pre-print]. doi: <https://doi.org/10.1101/2021.09.28.21264252>

Peña-Hernández MA, Klein J, Malik AA, et al. (2022). Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals. MedRxiv. [Pre-print]. doi: <https://dx.doi.org/10.1101/2021.12.28.21268460>

Pouwels KB, Pritchard E, Matthews PC, et al. (2021). Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine. 27(12): 2127-35. doi: <https://doi.org/10.1038/s41591-021-01548-7>

Prunas O, Warren JL, Crawford FW, et al. (2022). Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *Science*. 375(6585): 1151-4. doi: <https://dx.doi.org/10.1126/science.abl4292>

Puhach O, Adea K, Hulo N, et al. (2022). Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. *MedRxiv*. [Pre-print]. doi: <https://dx.doi.org/10.1101/2022.01.10.22269010>

Qassim SH, Chemaitelly H, Ayoub HH, et al. (2022). Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2022.03.02.22271771>

Regev-Yochay G, Amit S, Bergwerk M, et al. (2021). Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel *Lancet Regional Health Europe*. 7: 100150. doi: <https://doi.org/10.1016/j.lanepe.2021.100150>

Riemersma KK, Grogan BE, Kita-Yarbro A, et al. (2021). Shedding of infectious SARS-CoV-2 despite vaccination. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.07.31.21261387>

Salo J, Hägg M, Kortelainen M, et al. (2021). The indirect effect of mRNA-based COVID-19 vaccination on unvaccinated household members. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.05.27.21257896>

Salvatore PP, Lee CC, Sleweon S, et al. (2021). Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2021.11.12.21265796>

Servellita V, Morris MK, Sotomayor-Gonzalez A, et al. (2022). Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. *Nature Microbiology*. 7(2): 277-88. doi: <https://dx.doi.org/10.1038/s41564-021-01041-4>

Shah ASV, Gribben C, Bishop J, et al. (2021). Effect of vaccination on transmission of SARS-CoV-2. *New England Journal of Medicine*. 385(18): 1718-20. doi: <https://doi.org/10.1056/NEJMc2106757>

Shrotri M, Krutikov M, Palmer T, et al. (2021). Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Infectious Diseases*. 21(11): 1529-38. doi: <https://dx.doi.org/10.1016/S1473-3099%2821%2900289-9>

Siddle KJ, Krasilnikova LA, Moreno GK, et al. (2022). Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. *Cell*. 185(3): 485-92.e10. doi: <https://dx.doi.org/10.1016/j.cell.2021.12.027>

Singanayagam A, Hakki S, Dunning J, et al. (2021). Community transmission and viral load kinetics of the SARS-CoV-2 Delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infectious Diseases*. 22(2): 183-95. doi: [https://doi.org/10.1016/S1473-3099\(21\)00648-4](https://doi.org/10.1016/S1473-3099(21)00648-4)



Smith DR, Singh C, Green J, et al. (2022). Genomic and virological characterization of SARS-CoV-2 variants in a subset of unvaccinated and vaccinated U.S. military personnel. *Frontiers in Medicine*. 8: 836658. doi: <https://doi.org/10.3389/fmed.2021.836658>

Sriraman K, Shaikh A, Vaswani S, et al. (2022). Impact of Delta and vaccination on SARS-CoV-2 transmission risk: lessons for emerging breakthrough infections. *MedRxiv*. [Pre-print]. doi: <https://doi.org/10.1101/2022.03.02.22271385>

Tande AJ, Pollock BD, Shah ND, et al. (2021). Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening *Clinical Infectious Diseases*. 74(1): 59-65. doi: <https://doi.org/10.1093/cid/ciab229>

Thompson MG, Burgess JL, Naleway AL, et al. (2021). Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. *New England Journal of Medicine*. 385(4): 320-9. doi: <https://doi.org/10.1056/NEJMoa2107058>

Tricco A, Langlois E, Straus S. (2017). Rapid reviews to strengthen health policy and systems: a practical guide. Geneva: World Health Organization. Available at: <https://apps.who.int/iris/bitstream/handle/10665/258698/9789241512763-eng.pdf> [Accessed 24 May 2022].

UKHSA. (2022). The effect of vaccination on transmission of COVID-19. A rapid evidence briefing. A rapid evidence briefing. Update 1: Search to 12 January 2022. COVID-19 Rapid Evidence Service. UK Health Security Agency. Available at: [https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-detail.pl?biblionumber=64682&query\\_desc=The%20effect%20of%20vaccination%20on%20transmission%20of%20COVID-19](https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-detail.pl?biblionumber=64682&query_desc=The%20effect%20of%20vaccination%20on%20transmission%20of%20COVID-19) [Accessed 24 May 2022].

West S, King V, Carey TS, et al. (2002). Systems to rate the strength of scientific evidence. Evidence report/technology assessment No. 47. Agency for Healthcare Research and Quality. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK33881/> [Accessed 24 May 2022].

Williams GH, Llewelyn A, Brandao R, et al. (2021). SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom. *eClinicalMedicine*. 38: 101021. doi: <https://dx.doi.org/10.1016/j.eclinm.2021.101021>

Yi S, Kim JM, Choe YJ, et al. (2022). SARS-CoV-2 Delta variant breakthrough infection and onward secondary transmission in household. *Journal of Korean Medical Science*. 37(1): e12. doi: <https://dx.doi.org/10.3346/jkms.2022.37.e12>

## 10. Annex A: Methods

This is an update to a previously published review (UKHSA 2022), and employed a rapid review approach to address the review question:

*Does vaccination against SARS-CoV-2 affect transmission of SARS-CoV-2 to others in the subgroup of people who contract COVID-19 post-vaccination?*

We were also interested in the effects of vaccination on transmission according to vaccine type, individual vaccine brands, duration after vaccination, completion of the vaccination course, age and sex of index cases, SARS-CoV-2 variants in index cases, and background SARS-CoV-2 infection rate.

Our rapid review approach follows streamlined systematic methodologies (Tricco et al. 2017). In particular, 10% of the screening on title and abstract were screened in duplicate; full text screening, data extraction and risk of bias assessment were performed by one reviewer and checked by another. The review has been reported according to PRISMA guidelines (Page et al. 2021).

### Protocol

A protocol was produced by the project team before the literature search began, specifying the research question and the inclusion and exclusion criteria. The review was registered prospectively on PROSPERO (CRD42021257125).

### Review questions

1. What is the evidence on SARS-CoV-2 transmission from people who have had one or two doses of a COVID-19 vaccination?
2. How does risk of onward transmission vary with vaccine type, completion of the vaccination course, duration after vaccination, at different baseline community transmission levels and SARS-CoV-2 variant in the vaccinated person?

### Sources searched

Ovid Medline, Ovid Embase, CENTRAL, medRxiv and SSRN pre-prints, WHO COVID-19 Research Database.

## Search strategy

Searches were conducted for papers published between **12 January 2022** and **15 March 2022**. The previous review included the same search strategy for papers published between 22 October 2021 and 12 January 2022. Studies included in the previous review are also included in this review.

Search terms covered key aspects of the review question. The search strategy for Ovid Medline is presented in **Box A.1**. Additionally, we checked reference lists of relevant systematic reviews and evidence summaries and consulted with topic experts. All that had been identified as pre-prints as of **12 January 2022** were last checked and updated (if necessary) on 6 April 2022.

### Box A.1. Search strategy Ovid Medline

1. vaccinat\*.tw,kw.
2. vaccine\*.tw,kw.
3. previously-vaccin\*.tw,kw.
4. post-vaccin\*.tw,kw.
5. early-vaccin\*.tw,kw.
6. late-vaccin\*.tw,kw.
7. moderna.tw,kw.
8. mRNA-1273.tw,kw.
9. pfizer.tw,kw.
10. BNT162b2.tw,kw.
11. JNJ-78436735.tw,kw.
12. "Johnson & Johnson".tw,kw.
13. Astrazeneca.tw,kw.
14. Oxford-Astrazeneca.tw,kw.
15. AZD 1222.tw,kw.
16. AZD1222.tw,kw.
17. BNT 162b2.tw,kw.
18. ChAdOx1.tw,kw.
19. Novavax.tw,kw.
20. NVX-CoV2373.tw,kw.
21. Sputnik V.tw,kw.
22. Ad26.tw,kw.
23. "Ad26.COV2".tw,kw.
24. Ad5.tw,kw.
25. Janssen.tw,kw.
26. Sinovac.tw,kw.
27. sinopharm.tw,kw.
28. covaxin.tw,kw.
29. exp Vaccination/
30. COVID-19 Vaccines/
31. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (breakthrough or break through).tw,kw.
33. transmiss\*.tw,kw.
34. transmit\*.tw,kw.
35. viral load\*.tw,kw.
36. viral burden.tw,kw.
37. ((severity or severe) adj2 (disease or illness)).tw,kw.
38. Viral Load/
39. exp Disease Transmission, Infectious/
40. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. exp coronavirus/
42. exp Coronavirus Infections/
43. COVID-19/

44. ((corona\* or corono\*) adj1 (virus\* or viral\* or virinae\*)).ti,ab,kw.
45. (coronavirus\* or coronovirus\* or coronavirinae\* or CoV or HCoV\*).ti,ab,kw.
46. covid\*.nm.
47. (2019-nCoV or 2019nCoV or nCoV2019 or nCoV-2019 or COVID-19 or COVID19 or CORVID-19 or CORVID19 or WN-CoV or WNCov or HCoV-19 or HCoV19 or 2019 novel\* or Ncov or n-cov or SARS-CoV-2 or SARSCoV-2 or SARSCoV2 or SARS-CoV2 or SARSCov19 or SARS-Cov19 or SARSCov-19 or SARS-Cov-19 or Ncover or Ncorona\* or Ncorono\* or NcovWuhan\* or NcovHubei\* or NcovChina\* or NcovChinese\* or SARS2 or SARS-2 or SARScoronavirus2 or SARS-coronavirus-2 or SARScoronavirus 2 or SARS coronavirus2 or SARScoronavirus2 or SARS-coronavirus-2 or SARScoronavirus 2 or SARS coronavirus2).ti,ab,kw.
48. (respiratory\* adj2 (symptom\* or disease\* or illness\* or condition\*) adj10 (Wuhan\* or Hubei\* or China\* or Chinese\* or Huanan\*)).ti,ab,kw.
49. ((seafood market\* or food market\* or pneumonia\*) adj10 (Wuhan\* or Hubei\* or China\* or Chinese\* or Huanan\*)).ti,ab,kw.
50. ((outbreak\* or wildlife\* or pandemic\* or epidemic\*) adj1 (Wuhan\* or Hubei or China\* or Chinese\* or Huanan\*)).ti,ab,kw.
51. or/41-50
52. 31 and 40 and 51
53. COVID-19/tm [Transmission]
54. 31 and 53
55. COVID-19 Vaccines/
56. 40 and 55
57. COVID-19/vi [Virology]
58. 31 and 57
59. 52 or 54 or 56 or 58

## Inclusion and exclusion criteria

Article eligibility criteria are summarised in **Table A.1**.

In the protocol, we stated we would include disease severity as an outcome. However, as more transmission evidence became available, the need to include disease severity as a secondary outcome became less necessary, and as with the previous review, we focussed this review on transmission and viral load only. We also stated in the protocol that we would exclude studies where the only index cases were children, as they were not eligible for vaccination when the protocol was written. As in the previous review, we have removed this exclusion criteria. We have also removed the need for contacts to be unvaccinated in transmission studies from the inclusion criteria.

**Table A.1. Inclusion and exclusion criteria**

	Included	Excluded
Population	People who developed laboratory-confirmed symptomatic or asymptomatic COVID-19 (index cases)	
Settings	All community settings, including households	Healthcare settings
Context	COVID-19 pandemic	Other diseases

	Included	Excluded
Intervention / exposure	Partial, full or booster vaccination against COVID-19; any COVID-19 specific vaccination	
Outcomes	<p><b>Direct outcomes</b></p> <ul style="list-style-type: none"> <li>• Secondary transmission</li> <li>• Transmission of laboratory-confirmed SARS-CoV-2 to contacts (secondary cases, assessed as transmission by genomic analysis or proximity, such as household members)</li> </ul> <p><b>Indirect outcomes</b></p> <ul style="list-style-type: none"> <li>• Viral load</li> <li>• Duration of infection (if presented with a direct outcome or viral load)</li> </ul>	
Language	English	
Date of publication	12 January 2022 to 15 March 2022	
Study design	<ul style="list-style-type: none"> <li>• Randomised controlled trials</li> <li>• Cohort study</li> <li>• Case-control study</li> </ul> <p>The eligibility criteria for the update review were expanded slightly to include non-comparative studies reporting transmission rates for the Omicron (or different variants) in vaccinated populations.</p>	<ul style="list-style-type: none"> <li>• Systematic or narrative reviews</li> <li>• Guidelines</li> <li>• Opinion pieces</li> <li>• Outbreak investigations, unless they include an analytical component</li> </ul>
Publication type	Published and pre-print	

## Screening

Title and abstract screening were completed by 2 reviewers: 10% of the eligible studies were screened in duplicate (disagreements were resolved by discussion) and the remainder were screened by 1 reviewer.

Full text screening was completed by one reviewer and checked by a second.

The PRISMA diagram showing the flow of citations is provided in **Figure A.1**.

## Data extraction and risk of bias assessment


Data extraction was completed by 1 reviewer and checked by a second. Only results directly relevant to the review questions were extracted.

Studies were assessed using the quality criteria checklist (QCC) for primary research (Academy of Nutrition and Dietetics 2016). This risk of bias tool can be applied to most study designs (observational and interventional) and is therefore suitable for rapid reviews of mixed type of evidence. It is composed of 10 validity questions based on the criteria and domains identified by the Agency for Healthcare Research and Quality to assess the methodological quality of a study (that is, the extent to which a study has minimised selection, measurement and confounding biases) (West et al. 2002). In the QCC tool, 4 questions are considered critical (on selection bias, group comparability/confounding, interventions/exposure and outcome). A study will be rated as high quality if the answers to the 4 critical questions are 'yes' (and at least one additional 'yes'). The study will be rated as low quality if 2 or more of the critical questions are answered 'no' and/or if  $\geq 50\%$  of the remaining questions are answered 'no'. Otherwise, the study will be rated as medium quality. Judgments were made on case by case for questions answered as 'unclear'. To note that we report these ratings as 'quality' ratings for consistency with the name of the tool, although here quality needs to be understood as 'methodological quality' as part of a risk of bias assessment.

QCC ratings are reported in the data extraction tables, [Supplementary Tables 1 and 2](#) .

Variations across populations and subgroups, for example cultural variations or differences between ethnic, social or vulnerable groups were considered, where evidence was available.

Figure A.1. PRISMA diagram (for updated review)



## 11. About the Wales COVID-19 Evidence Centre

The WCEC integrates with worldwide efforts to synthesise and mobilise knowledge from research.

We operate with a core team as part of [Health and Care Research Wales](#), are hosted in the [Wales Centre for Primary and Emergency Care Research \(PRIME\)](#), and are led by [Professor Adrian Edwards of Cardiff University](#).

The core team of the centre works closely with collaborating partners in [Health Technology Wales](#), [Wales Centre for Evidence-Based Care](#), [Specialist Unit for Review Evidence centre](#), [SAIL Databank](#), [Bangor Institute for Health & Medical Research/ Health and Care Economics Cymru](#), and the [Public Health Wales Observatory](#).

Together we aim to provide around 50 reviews per year, answering the priority questions for policy and practice in Wales as we meet the demands of the pandemic and its impacts.

**Director:**

Professor Adrian Edwards

**Contact Email:**

[WC19EC@cardiff.ac.uk](mailto:WC19EC@cardiff.ac.uk)

**Website including report library:** <https://healthandcareresearchwales.org/about-research-community/wales-covid-19-evidence-centre>

**Prepared by:** Jessica Williams, Lauren Elston, Jenni Washington and Thomas Winfield from [Health Technology Wales](#)